使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to Baxter International's Fourth Quarter Earnings Conference Call. Your lines will remain in listen-only mode until the question and answer segment of today's call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
歡迎參加百特國際第四季財報電話會議。在今日電話會議的問答環節開始前,您的線路將維持僅收聽模式。(接線員指示)提醒您,本次電話會議由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如您有任何異議,請立即中斷連線。
I would now like to turn the call over to Ms. Mary Kay Ladone, Corporate Vice President, Investor Relations at Baxter International. Ms. Ladone, you may begin.
現在我想將電話會議交給百特國際投資人關係部企業副總裁 Mary Kay Ladone 女士。Mary Kay Ladone 女士,您可以開始了。
Mary Kay Ladone - Corporate VP, IR
Mary Kay Ladone - Corporate VP, IR
Thanks, Sean. Good morning and welcome to our Q4 2011 earnings conference call. Joining me today are Bob Parkinson, CEO and Chairman of Baxter International; Bob Hombach, Chief Financial Officer; and Dr. Norbert Riedel, Chief Science and Innovation Officer.
謝謝你,Sean。各位早安,歡迎參加我們 2011 年第四季財報電話會議。今天與我一同出席的有百特國際執行長兼董事長 Bob Parkinson、財務長 Bob Hombach,以及首席科學與創新長 Norbert Riedel 博士。
Before we get started, let me remind you that this presentation includes comments regarding our financial outlook, new product developments, and regulatory matters contain forward-looking statements that involve risks and uncertainties and of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially.
在開始之前,提醒各位,本次簡報包含關於我們財務展望、新產品開發與法規事項的評論,其中包含前瞻性陳述,涉及風險與不確定性;當然,我們的實際結果可能與目前預期有重大差異。關於可能導致實際結果與預期有重大差異的因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得更詳細資訊。
In addition, in today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website. Now, I'd like to turn the call over to Bob Parkinson.
此外,在今天的電話會議中,將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標的調節表,已包含於我們今早發布並可於官網取得的財報新聞稿中。現在,我想把電話會議交給 Bob Parkinson。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Thanks, Mary Kay. Good morning, thanks for calling in. As I've had the opportunity to reflect on 2011, I can tell you that I'm very pleased with the progress our Company continues to make financially, operationally, and scientifically. In fact, despite the global macro environment, competitive landscape, and ongoing uncertainty, Baxter continues to report strong financial results. This includes record sales and earnings for 2011, as you saw this morning, while accelerating investments in innovation, advancing our new product pipeline and pursuing other initiatives to enhance long-term growth, while returning significant value to our shareholders.
謝謝你,Mary Kay。各位早安,感謝來電參與。回顧 2011 年,我可以告訴各位,我對公司在財務、營運與科學方面持續取得的進展感到非常滿意。事實上,儘管全球總體環境、競爭態勢以及持續的不確定性,百特仍持續繳出強勁的財務成果。如各位今早所見,2011 年我們創下銷售與獲利新高;同時加速對創新的投資、推進新產品研發管線,並推動其他有助於提升長期成長的計畫,同時也為股東回饋可觀價值。
As you saw in our press release issued earlier this morning, adjusted EPS in the fourth quarter increased 5% to $1.17 per diluted share. For the full year, adjusted EPS was $4.31, which exceeded our original guidance range provided last January of $4.15 to $4.25 per diluted share.
如各位今早稍早發布的新聞稿所見,第四季調整後每股盈餘(EPS)成長 5%,至每股稀釋後 1.17 美元。全年調整後 EPS 為 4.31 美元,超出我們去年 1 月提供的原始指引區間(每股稀釋後 4.15 至 4.25 美元)。
On a reported basis, worldwide sales in the fourth quarter increased 3%, and after adjusting for the US multi-source generic injectable divestiture, sales growth was 4%. For the full-year 2011, worldwide sales increased 8%, or 5% after adjusting for foreign exchange and the divestiture. And we're particularly pleased with our continued ability to generate significant cash flow, which exceeded $2.8 billion for the year, while maintaining our disciplined capital allocation strategy of returning value to our shareholders through increased dividends and share repurchases.
以申報口徑計算,第四季全球銷售成長 3%;若調整美國多來源學名藥注射劑業務出售的影響,銷售成長為 4%。2011 全年全球銷售成長 8%;若調整匯率與出售案影響,成長為 5%。我們也特別滿意於持續創造可觀現金流的能力,全年超過 28 億美元;同時維持嚴謹的資本配置策略,透過提高股利與庫藏股回購,為股東回饋價值。
As some of you may know, in October, Baxter achieved an important milestone in celebrating our 80th anniversary, providing an opportunity to reflect on our great heritage as a pioneer and innovator in the development of life-saving, life-sustaining therapies for patients and customers around the world. As you've heard me say many times, innovation is our most important strategic priority, and 2011 was an outstanding year as we significantly increased our R&D investment to a record level. This has resulted in a meaningful new product pipeline that's as strong today as at any time in our Company's history; one that's focused on enhancing clinical outcomes, improving the safety and cost effectiveness of treatments, and expanding access to care.
部分各位可能知道,百特在 10 月達成一項重要里程碑,慶祝公司成立 80 週年,讓我們得以回顧作為先驅與創新者的卓越傳承,為全球病患與客戶開發拯救生命、維持生命的治療方案。如我多次提到,創新是我們最重要的策略優先事項;2011 年是非常出色的一年,我們將研發投資大幅提高至創紀錄水準。這也帶來了具實質意義的新產品研發管線,其強勁程度不亞於公司歷史上任何時期;聚焦於改善臨床結果、提升治療的安全性與成本效益,並擴大照護可近性。
I'm specifically encouraged with our pipeline achievements in 2011, as we advanced more than 20 key R&D programs within late stage clinical development. Many of these programs have the potential to profoundly improve the treatment and delivery of care for chronic diseases like hemophilia, immune deficiencies, Alzheimer's disease, and end-stage renal disease.
我尤其對我們 2011 年在研發管線的成果感到振奮,因為我們推進了超過 20 項關鍵研發計畫進入後期臨床開發階段。其中許多計畫有潛力大幅改善慢性疾病的治療與照護提供方式,例如血友病、免疫缺陷、阿茲海默症,以及末期腎臟病。
Let me take just a moment to highlight a number of these accomplishments. Within our leading hemophilia franchise, we've achieved a number of milestones. For example, we've now completed the global Phase I/II clinical trial of BAX 817, a recombinant Factor VIIa therapy and plan to advance into Phase III in early 2012. We've also completed enrollment in the Phase I/III clinical trial of BAX 326, our recombinant Factor IX treatment for hemophilia B and expect to conclude this trial and file for US approval in 2012.
我花一點時間重點說明其中幾項成果。在我們領先的血友病產品線中,我們達成多項里程碑。例如,我們已完成 BAX 817(重組第 VIIa 因子治療)的全球第 I/II 期臨床試驗,並計畫於 2012 年初推進至第 III 期。我們也已完成 BAX 326(用於 B 型血友病的重組第 IX 因子治療)第 I/III 期臨床試驗的受試者招募,並預期於 2012 年完成該試驗並向美國提出核准申請。
We recently announced the initiation of the Phase III trial of BAX 111, the first and only recombinant von Willebrand factor, which provides an alternative treatment option to currently marketed therapies that are plasma-derived. This is an exciting opportunity for Baxter with global market potential in excess of $300 million.
我們近期宣布啟動 BAX 111 的第 III 期試驗;BAX 111 是首個且唯一的重組 von Willebrand 因子,可提供目前市售之血漿來源療法以外的替代治療選項。這對百特而言是令人振奮的機會,全球市場潛力超過 3 億美元。
In December, ADVATE was approved by the FDA as the only factor-rate prophylactic treatment for both children and adults. The approval was based on a Phase IV prophylaxis study demonstrating that ADVATE significantly reduced median annual bleed rates in hemophilia A patients by 98%, representing a reduction from 44 bleeds when treated on demand to 1 when treated prophylactically. Of the two prophylactic regimens approved for use, the pharmacokinetic-driven dosing schedule of every three days offers some patients the choice of fewer infusions versus the current standard prophylaxis regimen.
12 月,ADVATE 獲 FDA 核准,成為唯一同時適用於兒童與成人的因子替代預防性治療。該核准係基於一項第 IV 期預防性治療研究,顯示 ADVATE 可將 A 型血友病患者的年度出血中位數顯著降低 98%,亦即從按需治療時的 44 次出血降至預防性治療時的 1 次。在獲核准的兩種預防性治療方案中,以藥物動力學為基礎、每三天一次的給藥時程,讓部分患者可選擇較少輸注次數,相較於目前的標準預防性治療方案。
Earlier this month, we announced the dosing of the first patients in a Phase I clinical trial of BAX 855, a longer-acting PEGylated factor VIII therapy based on the full-length ADVATE molecule. The Phase I results will serve as the foundation for advancing this important program through clinical development and determining whether BAX 855 can offer a treatment regimen requiring fewer infusions than ADVATE.
本月稍早,我們宣布在 BAX 855 的第 I 期臨床試驗中完成首批患者給藥;BAX 855 是一種長效 PEG 化第 VIII 因子療法,基於全長 ADVATE 分子。第 I 期結果將作為推進此重要計畫臨床開發的基礎,並用以判定 BAX 855 是否能提供較 ADVATE 需要更少輸注次數的治療方案。
In the area of immune deficiencies, we continue to be successful in driving differentiation of GAMMAGARD LIQUID by offering various dosage forms, enhancing delivery options, and expanding the number of approved indications. As you know, early in 2011, we introduced the first and only 30-gram dose vial for GAMMAGARD LIQUID in the US; the most frequently prescribed dose for primary immune deficiency patients, which enhances user convenience. We received FDA approval for GAMMAGARD LIQUID 10% SubQ, allowing Baxter to participate for the first time in this fast-growing segment of the PID market in the US.
在免疫缺陷領域,我們持續透過提供多種劑型、強化給藥/輸注選項,以及擴大核准適應症數量,成功推動 GAMMAGARD LIQUID 的差異化。如各位所知,2011 年初我們在美國推出 GAMMAGARD LIQUID 首個且唯一的 30 克劑量瓶,這是原發性免疫缺陷(PID)患者最常被處方的劑量,可提升使用便利性。我們也取得 GAMMAGARD LIQUID 10% SubQ 的 FDA 核准,使百特首次得以參與美國 PID 市場中快速成長的皮下給藥(SubQ)區隔。
We're pleased with the initial market acceptance as we've secured both share gains and conversions of Baxter patients to this new therapy and we expect to continue to capitalize on the differentiation we've achieved with this product's favorable tolerability profile, speed of infusion, and low infusion site reaction rate, included in our label of 2.7%.
我們對初期市場接受度感到滿意,因為我們同時取得市占提升,並促成百特患者轉換至此新療法;我們預期將持續運用此產品在耐受性良好、輸注速度快,以及輸注部位反應率低等差異化優勢。我們標籤所載的輸注部位反應率為 2.7%。
We also submitted HyQ for approval in the US, Europe, and Canada during 2011. HyQ allows for enhanced delivery of GAMMAGARD LIQUID subcutaneously, facilitated by recombinant human hyaluronidase. The regulatory submissions were based on results from a Phase III trial which met both its primary and secondary endpoints and were presented at the annual meeting of the American College of Asthma, Allergy, and Immunology in Boston.
我們也在 2011 年向美國、歐洲與加拿大提交 HyQ 的核准申請。HyQ 可在重組人類透明質酸酶的協助下,強化 GAMMAGARD LIQUID 的皮下給藥。這些法規申請係基於一項第 III 期試驗結果;該試驗同時達成主要與次要終點,並已於波士頓舉行的美國氣喘、過敏與免疫學學會年會上發表。
We also received approval in Europe for GAMMAGARD LIQUID, or KIOVIG, as a therapy for multi-focal motor neuropathy. This represents the first and only centrally licensed indication for MMN in that region and Baxter's first chronic neurological indication. We also recently completed the Phase III MMN clinical trial and submitted for approval in the US, where we've been granted Orphan Drug status.
我們也在歐洲獲得 GAMMAGARD LIQUID(或稱 KIOVIG)作為多灶性運動神經病變(MMN)治療的核准。這代表該地區首個且唯一的集中式核准之 MMN 適應症,也是 Baxter 的首個慢性神經學適應症。我們也於近期完成 MMN 的第三期臨床試驗並已向美國提交核准申請,且已獲授予孤兒藥資格。
We enrolled the last patient in our first Phase III study for Alzheimer's in 2011 and expect to complete the trial by the end of this year. And earlier this week, we announced our plans to initiate a second confirmatory Phase III trial following a successful futility analysis that was conducted by the Data Safety Monitoring Board. It's important to note that the futility analysis is not an interim look and the trial remains blinded. However, the analysis indicated greater than a 20% statistical probability of success in achieving statistical significance in the primary efficacy outcomes.
我們於 2011 年在首項阿茲海默症第三期研究中納入最後一位病患,並預期在今年年底前完成該試驗。而在本週稍早,我們宣布計畫在資料安全監測委員會(Data Safety Monitoring Board)進行成功的無效性分析(futility analysis)後,啟動第二項確認性第三期試驗。需要注意的是,無效性分析並非期中檢視,且試驗仍維持盲態。然而,該分析顯示在主要療效終點達到統計顯著性的成功機率大於 20%。
In our regenerative medicine business, we achieved a number of milestones including the approval and US launch of ARTISS fibrin sealant for use in facial surgery and the US regulatory filing for TISSEEL fibrin sealant for vascular surgery, providing a broad hemostasis label.
在我們的再生醫學業務中,我們達成多項里程碑,包括 ARTISS 纖維蛋白封合劑獲准並於美國上市用於顏面手術,以及就 TISSEEL 纖維蛋白封合劑用於血管手術向美國監管機關提交申請,提供更廣泛的止血適應症標示。
As we previously mentioned, we're very pleased with the publication of data from Baxter's Phase II chronic myocardial ischemia adult stem cell program, which was published in the scientific journal Circulation Research. Results from the trial demonstrate that injection of the patient's own CD34+ adult stem cells into targeted sites in the heart have therapeutic benefits, such as reduced angina episodes and improved exercise tolerance. We look forward to moving into a Phase III clinical trial early this year.
如同我們先前提及,我們對 Baxter 慢性心肌缺血成人幹細胞第二期計畫數據的發表感到非常滿意,該研究已刊登於科學期刊《Circulation Research》。試驗結果顯示,將病患自身的 CD34+ 成人幹細胞注射至心臟的特定部位具有治療效益,例如減少心絞痛發作次數並改善運動耐受度。我們期待在今年年初進入第三期臨床試驗。
And finally, we initiated our first home hemodialysis trial, which has the potential to deliver enhanced clinical outcomes and greater patient convenience to those with end-stage renal disease. The first US clinical study will assess device performance and safety in patients undergoing in-center hemodialysis and multiple trials are planned in the US and Canada to support CE Mark in 2013 and the US launch in 2014. These achievements depict just a handful of the programs in our pipeline that will present great opportunities for Baxter in the years to come. And I'm increasingly encouraged with our progress and we look forward to updating you on further R&D achievements in the future.
最後,我們啟動了首項居家血液透析試驗,該試驗有潛力為末期腎臟病患者帶來更佳的臨床結果與更高的便利性。首項美國臨床研究將評估在院內接受血液透析之患者的裝置效能與安全性,並規劃在美國與加拿大進行多項試驗,以支持 2013 年取得 CE 標誌以及 2014 年在美國上市。這些成果僅呈現我們研發管線中部分計畫,未來數年將為 Baxter 帶來重大機會。我對我們的進展愈發受到鼓舞,也期待未來向各位更新更多研發成果。
Throughout 2011, we also accelerated the pace of business development with several new business partnerships that complement our current businesses, enhance our product portfolio, and leverage our scientific, manufacturing and commercial capabilities. Some examples include the acquisition of Prism Pharmaceuticals, a specialty pharmaceutical company that developed and received FDA approval for NEXTERONE.
在 2011 年期間,我們也透過多項新的業務合作夥伴關係加快業務發展步伐,以補強現有業務、強化產品組合,並運用我們的科學、製造與商業化能力。例如,我們收購了 Prism Pharmaceuticals,這是一家專科製藥公司,開發並取得 NEXTERONE 的 FDA 核准。
Second, we acquired Baxa Corporation, which complements Baxter's global portfolio of nutritional therapies and drug delivery systems, leverages our global footprint and leadership in the hospital pharmacy, and supports patient safety.
第二,我們收購了 Baxa Corporation,該公司補強 Baxter 在營養治療與藥物輸送系統的全球產品組合,運用我們在醫院藥局領域的全球佈局與領導地位,並支持病患安全。
Third, we recently announced a definitive agreement to acquire Synovis, an acquisition that complements and expands Baxter's regenerative medicine and biosurgery franchise, including a number of devices and biological products for hemostasis, tissue sealing, and adherence.
第三,我們近期宣布已簽署收購 Synovis 的最終協議;此項收購可補強並擴大 Baxter 的再生醫學與生物外科事業群,涵蓋多項用於止血、組織封合與黏附的裝置與生物性產品。
And finally, we entered into a collaboration with Momenta to develop and commercialize follow-on biologic products, also known as biosimilars. With this collaboration, Baxter will leverage its leading clinical development and biologic manufacturing expertise, global leadership in injectables, and global commercial capabilities, while Momenta will provide its expertise in high-resolution analytics, characterization, and product and process development. This collaboration complements our early stage pipeline and allows us to expand our leadership and leverage our expertise and capabilities in biologics at a time when the global regulatory pathway for approval is becoming more evident.
最後,我們與 Momenta 展開合作,以開發並商業化後續生物製劑(follow-on biologic products),亦稱生物相似藥(biosimilars)。透過此合作,Baxter 將運用其領先的臨床開發與生物製造專業、在注射劑領域的全球領導地位,以及全球商業化能力;而 Momenta 將提供其在高解析度分析、特性鑑定,以及產品與製程開發方面的專長。此合作可補強我們的早期研發管線,並使我們得以在全球核准監管途徑日益明朗之際,擴大領導地位並運用我們在生物製劑方面的專業與能力。
These transactions reflect our intent of being more proactive on the business development front going forward and they also exemplify the types of opportunities we will pursue; those that complement our existing portfolio and expand our market-leading positions, leverage our global footprint, channel our customer relationships, capitalize on our core scientific or manufacturing capabilities, and provide for low integration risk and a higher confidence in achieving success.
這些交易反映我們未來在業務發展方面將更積極主動的意圖,也體現我們將追求的機會類型:能補強既有產品組合並擴大我們的市場領先地位、運用全球佈局、導入客戶關係、掌握核心科學或製造能力,且整合風險較低並更有把握達成成功。
As always, I'd be happy to address any questions on these or other topics, during the Q&A. With that, I'd like to ask Bob to review our fourth quarter financial results and guidance for 2012 in more detail, and then I'll come back to provide some closing perspectives. Bob?
一如往常,我很樂意在問答環節就這些或其他主題回答任何問題。接下來,我想請 Bob 更詳細地回顧我們第四季財務結果以及 2012 年的指引,之後我會再回來提供一些結語觀點。Bob?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Thanks, Bob, and good morning, everyone. As Bob mentioned, earnings per diluted share in the fourth quarter, excluding special items, increased 5% to $1.17 per diluted share, which was at the high end of our guidance range of $1.15 to $1.18 per diluted share. As we mentioned in our press release, our GAAP results include after-tax special items of approximately $200 million, or $0.35 per diluted share. Approximately 35% of this charge is non-cash.
謝謝你,Bob,各位早安。如 Bob 所提,第四季稀釋後每股盈餘(不含特殊項目)成長 5% 至每股 1.17 美元,位於我們每股 1.15 至 1.18 美元指引區間的高端。如同我們在新聞稿中提到,我們的 GAAP 結果包含稅後特殊項目約 2 億美元,或稀釋後每股 0.35 美元。其中約 35% 為非現金費用。
The special items primarily include costs associated with a business optimization initiative pertaining to certain manufacturing and business operations around the world. These actions include the elimination of a number of positions as we continue to streamline our international operations, rationalize our manufacturing footprint, and optimize our general and administrative infrastructure. Annual savings are expected to total approximately $0.12 per share when fully implemented in 2014.
特殊項目主要包括與一項業務最佳化計畫相關的成本,該計畫涉及全球若干製造與營運活動。這些行動包括裁減若干職位,因我們持續精簡國際營運、合理化製造據點布局,並最佳化一般與行政基礎架構。在 2014 年全面落實後,預期年度節省金額合計約為每股 0.12 美元。
For 2012, savings will equate to approximately $0.05 per diluted share, which is in addition to an incremental $0.03 of savings related to our actions implemented throughout 2011. Additionally, the Q4 charge includes certain asset impairments principally related to write-down of the Company's Greek government bonds.
2012 年的節省金額約相當於稀釋後每股 0.05 美元,此外,還有與我們在 2011 年期間所採取行動相關的額外每股 0.03 美元節省。另外,第四季費用亦包含若干資產減損,主要與本公司希臘政府債券的減記相關。
Now, let me briefly walk you through the P&L by line item for the fourth quarter and full-year 2011 before turning to our financial outlook for 2012. Starting with sales, worldwide sales totaled $3.6 billion in the fourth quarter and increased 3%. Foreign currency did not impact sales growth; therefore, growth on a constant currency basis was also 3% and in line with our guidance range of sales growth in the 2% to 3% range. Excluding the US multi-source injectables divestiture, Q4 sales growth was 4% on both a reported and constant currency basis.
現在,在轉向我們對 2012 年的財務展望之前,我先簡要按損益表各項目帶各位回顧第四季與 2011 全年的表現。先從銷售額開始,第四季全球銷售額合計 36 億美元,成長 3%。外幣匯率對銷售成長沒有影響;因此,以固定匯率計算的成長亦為 3%,並符合我們先前給出的 2% 至 3% 銷售成長指引區間。若排除美國多來源注射劑業務的處分,第四季銷售成長在報告基礎與固定匯率基礎下皆為 4%。
For the full year, global sales increased 6% to $13.9 billion. Excluding foreign currency and the impact of the US multi-source generic injectable divestiture, sales growth was 5%.
全年而言,全球銷售額成長 6% 至 139 億美元。若排除外幣匯率與美國多來源學名注射劑業務處分的影響,銷售成長為 5%。
In terms of the individual business performances, beginning with BioScience, global BioScience sales of $1.6 billion increased 3% in the fourth quarter, both on a reported and constant currency basis. For the full year, global BioScience sales of $6.1 billion increased 7%, or 5% excluding foreign currency.
就各事業的個別表現而言,先從 BioScience 開始,第四季 BioScience 全球銷售額為 16 億美元,按報告基礎與固定匯率基礎皆成長 3%。全年 BioScience 全球銷售額為 61 億美元,成長 7%;若排除外幣匯率則成長 5%。
Within the product categories, recombinant sales of $578 million advanced 8%. Excluding foreign currency, sales grew 7%, with balanced growth between both the US and international markets. On a year-to-date basis, recombinant sales exceeded $2.2 billion and excluding the negative impact of tenders, full-year recombinant growth on a constant currency basis was in mid-single digits, consistent with global market demand.
在產品類別方面,重組產品銷售額為 5.78 億美元,成長 8%。若排除外幣匯率,銷售成長 7%,美國與國際市場皆呈現均衡成長。以年初至今計,重組產品銷售額超過 22 億美元;若排除標案(tenders)的負面影響,全年以固定匯率計算的重組產品成長為中個位數百分比,與全球市場需求一致。
Moving on to plasma proteins, sales in the quarter were $397 million and declined 4% versus the prior-year period. On a constant currency basis, sales declined 2% despite a sequential increase in revenues of approximately 12%. This was primarily the result of a difficult comparison to last year, given the phasing of tenders.
接著看血漿蛋白,該季銷售額為 3.97 億美元,較去年同期下滑 4%。以固定匯率計算,銷售下滑 2%,儘管營收較前一季增加約 12%。這主要是因為與去年相比的比較基期較為艱難,原因在於標案時點的分配。
In addition, the decline in sales can be attributed to two items -- timing of plasma-derived Factor VIII shipments related to a large Brazilian tender and temporary supply constraints and delays in the clearance of shipments in China resulting in back orders of approximately $15 million. Excluding these items, sales growth for the plasma protein category was in mid-single digits. For the full-year, plasma protein sales exceeded $1.4 billion and increased 5% on both a reported and constant currency basis.
此外,銷售下滑可歸因於兩項因素——與巴西一項大型標案相關之血漿衍生第八凝血因子(Factor VIII)出貨時點,以及中國暫時性的供應限制與出貨通關延遲,導致約1,500萬美元的積壓訂單。排除上述因素後,血漿蛋白類別的銷售成長為中個位數百分比。全年而言,血漿蛋白銷售額超過14億美元,按報告基礎及固定匯率基礎均成長5%。
In antibody therapy, sales of $406 million increased 5%. Excluding foreign currency, sales were up 6%, driven by a robust demand for GAMMAGARD LIQUID, particularly in the US, and the successful launch of our SubQ therapy. As you know, Octapharma returned to the market on a global basis and we annualized the benefits of their absence in the fourth quarter. Excluding the Octapharma benefit from both years, sales growth in the fourth quarter for antibody therapy on a constant currency basis was approximately 10%. For the full-year, antibody therapy sales exceeded $1.5 billion and increased 14% versus 2010, or 13% on a constant currency basis, faster than market demand.
在抗體治療方面,銷售額4.06億美元,成長5%。排除匯率影響後,銷售成長6%,主要受GAMMAGARD LIQUID需求強勁(尤其在美國)以及我們皮下(SubQ)療法成功上市所帶動。如各位所知,Octapharma已在全球範圍重返市場,而我們在第四季已將其缺席所帶來的效益年化。若將兩年度的Octapharma效益均排除,抗體治療在第四季按固定匯率基礎的銷售成長約為10%。全年而言,抗體治療銷售額超過15億美元,較2010年成長14%,或按固定匯率基礎成長13%,增速快於市場需求。
As we previously mentioned, our full-year results included a benefit of approximately $100 million in sales related to meeting demand previously served by Octapharma.
如我們先前提到,全年業績包含約1億美元的銷售效益,係來自滿足先前由Octapharma供應的需求。
In the fourth quarter, sales in regenerative medicine, which includes our BioSurgery products, totaled $150 million and increased 3% on both a reported and constant currency basis. High single-digit growth of our surgical sealants was offset by lower ACTIFUSE revenues resulting from our planned transition to a direct sales model from ApaTech's former distributor model, as we've discussed in previous quarters.
第四季,再生醫學(包含我們的BioSurgery產品)銷售額合計1.50億美元,按報告基礎及固定匯率基礎均成長3%。我們手術封合劑的高個位數成長,被ACTIFUSE營收下滑所抵銷;該下滑源於我們按計畫將銷售模式由ApaTech先前的經銷商模式轉為直銷模式,正如我們在前幾季所討論。
For the full-year, regenerative medicine sales of $580 million increased 10% or 8% on a constant currency basis, despite global weakness in surgical procedures.
全年而言,再生醫學銷售額5.80億美元成長10%,或按固定匯率基礎成長8%,儘管全球手術量疲弱。
Finally, revenues in the other category, which includes vaccines, totaled $44 million in the fourth quarter and declined 16% versus the prior year. This is primarily due to a benefit in 2010 from one-time orders for our meningitis C vaccine that did not recur in 2011.
最後,其他類別(包含疫苗)第四季營收合計4,400萬美元,較去年同期下滑16%。主要原因是2010年曾受惠於一次性腦膜炎C型疫苗訂單,而2011年未再出現。
In Med Products, global sales in the fourth quarter totaled approximately $2 billion, reflecting an increase of 3%, or 2% on a constant currency basis. Adjusting for the US multi-source generic injectables divestiture, reported sales growth for Medical Products was 6%, or 5% on a constant currency basis.
在醫療產品(Med Products)方面,第四季全球銷售額約20億美元,反映成長3%,或按固定匯率基礎成長2%。若調整美國多來源學名注射劑業務的出售影響,醫療產品的報告銷售成長為6%,或按固定匯率基礎成長5%。
For the full year, excluding the prior-year COLLEAGUE charge, Medical Products sales of $7.8 billion increased 6% and on a constant currency basis, sales increased 3%. Also, after adjusting for the divestiture, full-year sales growth was 8%, or 5% on a constant currency basis.
全年而言,排除前一年度COLLEAGUE費用後,醫療產品銷售額78億美元成長6%;按固定匯率基礎,銷售成長3%。此外,若再調整出售影響,全年銷售成長為8%,或按固定匯率基礎成長5%。
Now, turning to the product categories, renal sales in the quarter totaled $664 million and increased 6% on a reported basis. Excluding foreign currency, sales growth of 5% was driven primarily by global PD growth of 8%, which was partially offset by the continued loss of PD patients to another US service provider and lower HD revenues.
接著看各產品類別,腎臟相關銷售本季合計6.64億美元,按報告基礎成長6%。排除匯率影響後,5%的銷售成長主要由全球腹膜透析(PD)8%的成長所帶動,但部分被美國PD病患持續流失至另一家服務供應商以及血液透析(HD)營收較低所抵銷。
I'd mentioned we continue to be pleased with the ongoing momentum in patient gains in the US given recent reimbursement changes and solid patient growth across Latin America and Asia. Sales in the global injectables category of $487 million declined 2% and excluding foreign currency, sales declined 3%. Excluding the divestiture, growth of this category was 10%, or 9% on a constant currency basis, resulting from strong growth in our compounding business, as well as a robust demand for MINI-BAGS and certain injectable drugs.
我先前提到,鑑於近期給付制度變動,以及拉丁美洲與亞洲病患人數穩健成長,我們對美國病患淨增的持續動能仍感到滿意。全球注射劑類別銷售額4.87億美元下滑2%,排除匯率影響後下滑3%。若排除出售影響,該類別成長10%,或按固定匯率基礎成長9%,主要來自我們調配(compounding)業務的強勁成長,以及MINI-BAGS與部分注射劑藥品的旺盛需求。
IV therapy sales totaled $469 million and rose 4% on both a reported and constant currency basis. Contributing to this performance was the addition of Baxa sales to our nutrition franchise, which totaled approximately $20 million, as well as strong growth of IV solutions in the US. Infusion systems sales totaled $235 million, reflecting growth of 2% on a reported and constant currency basis. Growth was the result of expanded placements and sales of the Spectrum Pump.
靜脈(IV)治療銷售額合計4.69億美元,按報告基礎及固定匯率基礎均成長4%。推動此表現的因素包括將Baxa銷售納入我們的營養產品線(約2,000萬美元),以及美國IV溶液的強勁成長。輸注系統銷售額合計2.35億美元,按報告基礎及固定匯率基礎成長2%。成長來自Spectrum Pump的裝機擴張與銷售增加。
Finally, anesthesia sales of $147 million increased 4% on a reported and constant currency basis, driven by solid demand in the US, primarily for Suprane and other critical care products. This growth was partially offset by competitive pricing pressures for generic sevoflurane.
最後,麻醉產品銷售額1.47億美元,按報告基礎及固定匯率基礎成長4%,主要由美國穩健需求所帶動,尤其是Suprane及其他重症照護產品。此成長部分被學名藥七氟醚(sevoflurane)的競爭性定價壓力所抵銷。
Turning to the rest of the P&L, gross margin for the Company was 51.8% in the fourth quarter, an improvement of 90 basis points sequentially and 180 basis points versus the prior year. Margin expansion in the quarter was primarily the result of mixed benefits derived from across the portfolio and improved manufacturing efficiencies in the plasma business. For the full year, gross margin was 51.4%, which is 30 basis points higher than the 2010 gross margin of 51.1% and in line with our full-year guidance.
接著看損益表其餘項目,公司第四季毛利率為51.8%,較第三季依序提升90個基點,較去年同期提升180個基點。本季毛利率擴張主要來自產品組合在整體產品線上的綜合效益,以及血漿業務製造效率提升。全年而言,毛利率為51.4%,較2010年的51.1%提高30個基點,並符合我們的全年指引。
SG&A totaled $748 million in the quarter and increased 6% versus the prior year period. Excluding foreign currency, SG&A increased 5% as incremental pension expense and investments in a number of promotional activities focused on upcoming new product launches were partially offset by business optimization savings and aggressive management of discretionary spending. For the full year, SG&A increased 7% with FX contributing 3 percentage points of growth and as a percent of sales, the SG&A ratio of 21.1% was flat to 2010.
本季銷售、一般及行政費用(SG&A)合計7.48億美元,較去年同期增加6%。排除匯率影響後,SG&A增加5%;新增的退休金費用以及針對即將推出的新產品上市所進行的多項推廣活動投資,部分被業務優化節省與對可自由支配支出的嚴格管理所抵銷。全年而言,SG&A增加7%,其中匯率貢獻3個百分點的成長;以銷售額百分比計,SG&A比率21.1%與2010年持平。
R&D spending accelerated in the fourth quarter to $254 million, representing an increase of 11%, as we continue to fund in advance a number of late-stage programs, several of which Bob mentioned earlier. R&D for the full year totaled $946 million, a new record level for the Company.
第四季研發(R&D)支出加速至2.54億美元,年增11%,因我們持續提前投入多項後期研發計畫,其中數項Bob先前已提及。全年研發支出合計9.46億美元,創公司新高。
The operating margin in the quarter was 23.9%; a sequential improvement of 20 basis points from the third quarter and the highest quarterly operating margin during 2011. For the full year, operating margin was 23.5%; an improvement over 2010 by 20 basis points, primarily a result of gross margin improvements.
本季營業利益率為23.9%;較第三季依序改善20個基點,亦為2011年最高的單季營業利益率。全年營業利益率為23.5%;較2010年提升20個基點,主要源於毛利率改善。
Interest expense was $15 million compared to $19 million last year. This reduction is primarily a result of a benefit from higher rate debt that matured last year and higher interest income. The tax rate was 20.4% in the quarter; in line with our expectations and similar to last year's rate. And finally, as previously mentioned, adjusted EPS was $1.17 per diluted share; an increase of 5%. For the full year, adjusted EPS was $4.31, representing an 8% increase.
利息費用為1,500萬美元,去年為1,900萬美元。此下降主要來自去年到期的較高利率債務所帶來的效益,以及利息收入增加。本季稅率為20.4%,符合我們預期,且與去年稅率相近。最後,如先前所述,調整後每股盈餘(EPS)為每股稀釋後1.17美元,成長5%。全年調整後EPS為4.31美元,代表成長8%。
Turning to cash flow, cash flow from operations in the quarter totaled $892 million compared to $935 million in the prior year period. The reduction versus the prior year is the result of $89 million in payments, primarily related to the infusion pump recall. On a full-year basis, cash flow from operations exceeded $2.8 billion compared to $3 billion last year. After adjusting for pension and the payments principally related to COLLEAGUE, cash flow from operations exceeded $3.3 billion.
接著看現金流,第四季營運活動現金流量合計8.92億美元,去年同期為9.35億美元。較去年同期減少的原因是支付了8,900萬美元款項,主要與輸注幫浦召回相關。以全年計,營運活動現金流量超過28億美元,去年為30億美元。若調整退休金以及主要與COLLEAGUE相關的付款,營運活動現金流量超過33億美元。
Capital expenditures of $960 million were similar to the prior-year period, resulting in free cash flow, excluding pension and other payments in excess of $2.3 billion. DSO ended the quarter at 53.5 days; an improvement sequentially, but one day higher than the year-end DSO in 2010. And inventory turns of 2.7 also improved sequentially, but were lower than last year.
資本支出為9.60億美元,與去年同期相近,因此自由現金流(不含超過部分的退休金及其他付款)超過23億美元。DSO於本季末為53.5天;較前一季改善,但較2010年年底的DSO高出1天。存貨周轉率為2.7,也較前一季改善,但低於去年。
And lastly, during 2011, we repurchased approximately 30 million shares of common stock for approximately $1.6 billion, or on a net basis, 20 million shares for approximately $1.2 billion, higher than our original objective.
最後,在2011年,我們回購了約3,000萬股普通股,金額約16億美元;或以淨額計算,回購約2,000萬股,金額約12億美元,高於我們原先的目標。
Finally, let me conclude my comments this morning by providing our financial outlook for the first quarter and full-year 2012. First, for the full year, we expect earnings of $4.47 to $4.59 per diluted share. This guidance includes a net headwind of approximately $0.25 per diluted share for non-operational items including incremental pension expense and the impact of foreign currency, particularly in emerging markets. By line item for the P&L and starting with sales, we project full-year sales growth of approximately 2%. Excluding foreign currency, sales growth will be in the 4% to 5% range, as foreign currency is assumed to have a 2% to 3% impact on top line.
最後,讓我在今天上午以提供我們對2012年第一季及全年財務展望來結束我的評論。首先,就全年而言,我們預期每股稀釋後盈餘為4.47至4.59美元。此指引包含每股稀釋後約0.25美元的淨逆風,來自非營運項目,包括退休金費用增加及外幣影響,尤其是在新興市場。就損益表各項目而言,先從銷售額開始,我們預估全年銷售成長約2%。若排除外幣因素,銷售成長將落在4%至5%區間,因假設外幣對營收(top line)的影響為2%至3%。
This outlook includes incremental sales from the Baxa and Synovis acquisitions of approximately $160 million and $65 million, respectively. The contribution from these acquisitions is more than offset by the impact of Octapharma, the difficult first quarter comparison resulting from the US multi-source generic injectable divestiture and other headwinds we've discussed.
此展望包含來自Baxa與Synovis收購案的增量銷售,分別約1.60億美元與6,500萬美元。這些收購的貢獻,已被Octapharma的影響、因美國多來源學名藥注射劑業務剝離所造成的第一季艱難比較基期,以及我們已討論過的其他逆風所抵銷且有餘。
We expect the full-year gross margin rate for the Company to be flat to modestly below the 2011 gross margin of 51.4%, as operational improvements of approximately 50 to 100 basis points are offset by a number of headwinds, primarily dilution from recent transactions and the impact of foreign currency and pension.
我們預期公司全年毛利率將與2011年51.4%的毛利率持平或小幅下降,因約50至100個基點的營運改善,將被多項逆風所抵銷,主要包括近期交易帶來的稀釋,以及外幣與退休金的影響。
We expect SG&A to grow in low single-digits and R&D to grow in low to mid-single digits for the year. Interest expense for the year will total approximately $80 million and other expense, including non-controlling interest, will be in the $20 million to $30 million range. We assume a tax rate of approximately 21.5%, flat with 2011, and a full-year average share count of 550 million to 555 million shares, which assumes approximately $1 billion in net share repurchases. From a cash flow perspective, we plan to generate cash flow from operations of more than $3 billion, which includes an outflow of approximately $250 million related to the finalization of the COLLEAGUE consent order.
我們預期SG&A全年將以低個位數成長,R&D全年將以低至中個位數成長。全年利息費用合計約8,000萬美元,其他費用(含非控制權益)約在2,000萬至3,000萬美元區間。我們假設稅率約21.5%,與2011年持平;全年平均流通股數為5.50億至5.55億股,該假設包含約10億美元的淨股票回購。就現金流角度而言,我們計畫產生超過30億美元的營運現金流,其中包含約2.50億美元的現金流出,與COLLEAGUE同意令的最終定案相關。
Now, to expand on full-year sales assumptions for each of the businesses. First, on a constant currency basis, we expect Medical Products sales to grow in mid-single digits. By product category, IV therapy sales will grow in high single-digits and as you know, this category includes the nutrition business and will benefit from the Baxa acquisition that closed in the fourth quarter. Anesthesia and global injectable sales will increase in mid-single digits, while infusion system sales will decline approximately 5%, reflecting a tough comparison for Sigma as we complete the consent order later this year. And lastly, we expect renal sales to grow in low single-digits.
接著,進一步說明各事業的全年銷售假設。首先,以固定匯率基礎計算,我們預期醫療產品(Medical Products)銷售將以中個位數成長。按產品類別來看,IV治療銷售將以高個位數成長;如各位所知,此類別包含營養業務,並將受益於第四季完成的Baxa收購。麻醉與全球注射劑銷售將以中個位數成長,而輸注系統銷售將下滑約5%,反映Sigma的艱難比較基期,因我們將於今年稍晚完成同意令。最後,我們預期腎臟相關銷售將以低個位數成長。
For BioScience, we project sales growth excluding foreign currency in mid-single digits. This includes low single-digit growth for recombinants, reflecting the impact of recent tenders and plasma protein sales growth in mid-single digits.
就BioScience而言,我們預估在排除外幣影響後,銷售成長為中個位數。其中包含重組蛋白(recombinants)低個位數成長(反映近期標案的影響),以及血漿蛋白銷售以中個位數成長。
For antibody therapy, sales of low-single digits reflecting robust underlying demand and a modest benefit related to our HyQ launch in the second half of 2012, both of which are partially offset by the impact of Octapharma. We expect regenerative medicine sales to grow approximately 20%, which includes the addition of Synovis, and finally, we expect the other category within BioScience to decline approximately 5%, driven primarily by lower third-party plasma sales.
就抗體治療而言,銷售為低個位數成長,反映強勁的基本需求,以及我們於2012年下半年推出HyQ所帶來的溫和助益;上述因素部分被Octapharma的影響所抵銷。我們預期再生醫學銷售成長約20%,其中包含Synovis的併入;最後,我們預期BioScience中的其他類別將下滑約5%,主要由第三方血漿銷售降低所致。
For the first quarter, as we mentioned in our press release, we expect earnings per diluted share of $0.98 to $1 and sales growth, excluding the impact of foreign currency, of approximately 2%. Based on our outlook for foreign exchange rates, we expect reported sales to be comparable to sales achieved in the first quarter of 2011. Thank you and now, I'll turn the call back over to Bob for his closing comments.
就第一季而言,如我們在新聞稿中提到的,我們預期每股稀釋後盈餘為0.98至1.00美元,且在排除外幣影響後,銷售成長約2%。基於我們對外匯匯率的展望,我們預期報告銷售額將與2011年第一季達成的銷售額相當。謝謝各位,接下來我把電話交回給Bob做結語。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Thanks, Bob. As I mentioned earlier, I'm quite pleased with our 2011 financial and operational accomplishments. We achieved organic sales growth of 5% and earnings per diluted share increased 8% on an adjusted basis. We generated strong sustainable cash flow of more than $2.8 billion and returned significant value to our shareholders.
謝謝,Bob。如我先前提到的,我對我們2011年的財務與營運成就感到相當滿意。我們達成5%的有機銷售成長,且以調整後基礎計算,每股稀釋後盈餘成長8%。我們創造了超過28億美元、強勁且可持續的現金流,並為股東回饋了可觀價值。
We meaningfully advanced our new product pipeline that's as strong today as any time in our history. We accelerated the pace of business development initiatives that complement our current businesses, leverage our capabilities, and provide enhanced growth in the future.
我們大幅推進了新產品研發管線,其強度在今天不亞於我們歷史上的任何時期。我們加速推動能補強現有事業、發揮我們能力並在未來帶來更高成長的業務發展計畫。
And culturally, we continue to respond to an evolving and demanding environment, with new strategies aimed at enhancing our commercial, operational, and scientific effectiveness, while continuing to focus on maximizing growth opportunities across the portfolio and managing costs throughout the Company.
在企業文化面,我們持續回應不斷演變且要求更高的環境,採取新策略以提升我們的商業、營運與科學效能,同時持續聚焦於在整體產品組合中最大化成長機會,並在全公司範圍內管理成本。
As a result, throughout 2011, we strengthened our foundation and we remain very confident in the long-term growth prospects for our Company. We plan to expand upon this later this year when we host an investor conference in Chicago. Additional details will be made available from Mary Kay to all of you in the coming weeks. With that, thank you, and let's now open up the call to Q&A.
因此,在2011年期間,我們強化了基礎,並對公司長期成長前景仍然非常有信心。我們計畫在今年稍晚於芝加哥舉辦投資人會議時,進一步擴充說明。未來幾週內,Mary Kay將向各位提供更多細節。就此,謝謝各位,現在讓我們開放進入問答。
Operator
Operator
(Operator Instructions) I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter International website for 30 days at www.baxter.com. Mike Weinstein, JPMorgan.
(接線員指示) 提醒各位與會者,本次電話會議將被錄音,並將於Baxter International網站提供30天的數位重播,網址為www.baxter.com。Mike Weinstein,JPMorgan。
Mike Weinstein - Analyst
Mike Weinstein - Analyst
Bob, can you update us on your plans for upgrading the old LA fractionation facility and tell us how that plays into your guidance for 2012?
Bob,你能否向我們更新你們升級舊LA分餾(fractionation)廠的計畫,並說明這如何納入你們對2012年的指引?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Yes, this is Bob Parkinson, Mike. Let me kick this off and then Bob and Mary Kay can augment my comments. As you know, we continue to see very steady long-term growth in demand for plasma-based therapies, including IG. Our estimates are that market demand continues to grow in certainly the strong mid single-digit range over time.
是的,Mike,我是Bob Parkinson。我先開場,接著Bob和Mary Kay可以補充我的評論。如你所知,我們持續看到以血漿為基礎的療法(包括IG)需求呈現非常穩健的長期成長。我們的估計是,市場需求隨時間推進,持續以強勁的中個位數區間成長。
We continue to make very good progress in transitioning manufacturing to new LA frac. I think last year we had the majority of our production now move to new LA frac. Obviously, given our strong pipeline of new products, our current plans include utilizing capacity -- as we've discussed before, in the old LA facility at least for some number of years.
我們在將製造轉移至新的LA分餾廠方面持續取得非常良好的進展。我認為去年我們的大部分產量已轉移至新的LA分餾廠。顯然,鑑於我們強勁的新產品管線,我們目前的計畫包括在舊LA廠(如我們先前討論過的)至少在若干年內利用其產能。
As a result of that, we need to shut down old LA to make the necessary investments to upgrade the facility. So, we can keep it in play over the longer-term. We plan on doing that really in the beginning of the second half, Mike, of 2012. We haven't defined a specific date, but it will be early in the second half.
因此,我們需要關閉舊LA廠,以進行必要的投資來升級該設施。如此一來,我們就能在更長期內持續使用它。Mike,我們計畫在2012年下半年一開始就進行這件事。我們尚未訂出具體日期,但會在下半年初期。
In the meantime, we've been able to adjust the scale of our operations successfully within the existing global manufacturing footprint -- between new LA, Vienna, Rieti, Italy, and through yield improvements and flexibility in the global network. We've been able to respond appropriately to demand.
同時,我們已能在既有的全球製造版圖內成功調整營運規模——在新的LA廠、維也納、義大利Rieti之間,並透過良率改善與全球網路的彈性。我們已能適切地回應需求。
Beyond keeping old LA frac in commission, as we've discussed before, given expansion of IG indications, the continued strong growth of plasma proteins over time, we have initiated a greenfield development process for a new site. We haven't arrived at a final decision in terms of site selection. We expect to do that shortly.
除了如同我們先前討論過的,持續讓舊的 LA 分餾廠維持運轉之外,鑑於 IG 適應症的擴大,以及血漿蛋白長期持續強勁成長,我們已啟動在新址進行綠地開發(greenfield development)的流程。在選址方面,我們尚未做出最終決定。我們預期很快就會完成。
Certainly, we'd be in a position in our investor conference this fall to share more specifics in terms of the overall capacity demand for plasma proteins, the role that the new facility -- the greenfield site will play in that over time. That covers the overall situation. Specifically, early second half of the year, we'll take old LA out of production to make the necessary upgrades things.
當然,在今年秋季的投資人會議上,我們將能分享更多細節,包括血漿蛋白整體產能需求,以及新設施——也就是綠地廠址——隨時間推進將在其中扮演的角色。以上涵蓋整體情況。具體而言,在下半年初期,我們會讓舊的 LA 停產,以進行必要的升級作業。
Mike Weinstein - Analyst
Mike Weinstein - Analyst
Bob, is the decision to wait to the second half so that you can build inventory in the first half of the year? And then how does taking it down in the second half impact your ability to launch IG?
Bob,把時間延到下半年,是不是為了讓你們能在上半年先建立庫存?另外,下半年停產會如何影響你們推出 IG 的能力?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Bob, why don't you comment on the inventory build --
Bob,你要不要先談談庫存建立——
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes. Absolutely. As you know, we've been running very tight on inventory. In fact, with very strong demand for our product, periodically experiencing back orders. With Octa returning to the market, the expectation is that we'll be in a better position to start building some inventory in advance of the shutdown in the back half of the year and be in better shape that way. That will allow us to maintain supply and support some modest growth as we indicated in our guidance.
是的。完全正確。如你所知,我們的庫存一直非常吃緊。事實上,由於產品需求非常強勁,我們不時會遇到缺貨待交(back orders)。隨著 Octa 回到市場,我們預期在今年下半年停機之前,將更有條件提前建立一些庫存,從而在供應面更為充裕。這將使我們能維持供應,並如我們在財測中所指出的,支撐一些溫和的成長。
I would say from a cost perspective, very modest impact to cost in 2012. Some impact to '13, but I would say a slight headwind, nothing significant. We're confident we'll be able to take it down, do the necessary upgrades and get back up in production in 2013, and support future growth very nicely.
我會說,從成本角度來看,2012 年對成本的影響非常有限。2013 年會有一些影響,但我會說只是輕微的逆風,並不顯著。我們有信心能讓它停下來、完成必要升級,並在 2013 年恢復生產,且能很好地支援未來成長。
Mike Weinstein - Analyst
Mike Weinstein - Analyst
Coming back to it, how does that impact the ability to really launch HyQ and go after CSL's business?
回到這點,這會如何影響真正推出 HyQ、並去爭取 CSL 的業務的能力?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
I think our approach, initially with HyQ, given that this is a paradigm change in treatment is to have a controlled launch, ensure that those patients and treaters that first go on the product understand how to administer it appropriately, build a good track record and good word-of-mouth amongst the community, and then drive the momentum going forward. Our expectations for HyQ for 2012 are modest in any case. We certainly expect to build a strong foundation so that we can gain some momentum in '13 and we'll have the production available to support that momentum as we go forward.
我認為我們對 HyQ 的做法,一開始會採取受控式上市(controlled launch),因為這在治療上是一種典範轉移;我們要確保最先使用該產品的病患與治療者了解如何正確施用,建立良好的使用紀錄與社群口碑,然後再推動後續動能。無論如何,我們對 2012 年 HyQ 的預期本來就較為保守。我們確實期望打下堅實基礎,以便在 2013 年取得一些動能,而我們也將具備可用產能來支援這股動能,隨著我們持續向前推進。
Mary Kay Ladone - Corporate VP, IR
Mary Kay Ladone - Corporate VP, IR
Mike, I'd also add that Octapharma, in terms of our guidance, we've actually eliminated the $100 million of benefit we received in 2011. So, that the guidance of low single-digits, if you excluded that $100 million benefit, would be in high single-digits, which is faster than the market growth.
Mike,我也補充一下,關於 Octapharma,在我們的財測中,我們其實已把 2011 年獲得的 1 億美元效益剔除了。因此,低個位數成長的財測,如果排除那 1 億美元效益,將會是高個位數成長,這比市場成長更快。
Mike Weinstein - Analyst
Mike Weinstein - Analyst
Got you, that's helpful. Let me just ask one question for Bob Hombach again. The first quarter guidance reflects flat to low single-digit EPS growth. Can you just provide a little bit more color on why the first quarter EPS growth would be lower than the balance of the year? Thanks.
了解,這很有幫助。我再問 Bob Hombach 一個問題。第一季的指引反映 EPS 成長持平到低個位數。你能否再多補充一些背景,為什麼第一季 EPS 成長會低於今年其餘季度?謝謝。
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes, a couple of factors there. The first quarter tends to be a lower quarter from a margin perspective. Certainly, given where FX rates are at the moment, that certainly poses a bit of a headwind for us as we go into the first quarter here. Really, FX from a headwind standpoint will be there for most of the year, as we indicated in our prepared comments.
好的,主要有幾個因素。第一季從毛利率角度來看通常是較低的一季。當然,考量目前匯率水準,這確實會在我們進入第一季時帶來一些逆風。實際上,正如我們在事先準備的發言中所提到的,從逆風角度來看,匯率在今年大部分時間都會存在。
But as we get through the first quarter, as we annualize out the impact of the divestiture, we did book revenues to the tune of about $50 million to $60 million related to the multi-source generic business in the first quarter of last year. That will annualize after the first quarter and have a bit more of a normalized growth rate beyond that.
但當我們度過第一季後,隨著我們把剝離(divestiture)的影響年化,去年第一季我們入帳了約 5,000 萬到 6,000 萬美元、與多來源學名藥業務相關的營收。這部分在第一季之後就會完成年化,之後的成長率會更趨於常態化。
Mike Weinstein - Analyst
Mike Weinstein - Analyst
Great. Thank you, guys.
很好。謝謝各位。
Operator
Operator
David Lewis, Morgan Stanley.
Morgan Stanley 的 David Lewis。
David Lewis - Analyst
David Lewis - Analyst
Maybe a couple questions for Bob Hombach -- Bob, just real quickly, on cash flow, you're guiding to cash flow from operations up year-on-year, but there are some pretty significant hits this year, specifically in pension, as well as the deliverables related to COLLEAGUE. Can you just help us understand your net-net, how you think underlying cash trends are trending into '12, when will we see a normalized cash quarter you think in 2012?
我可能有幾個問題要問 Bob Hombach——Bob,很快問一下,關於現金流,你們指引營運現金流(cash flow from operations)年增,但今年有一些相當顯著的支出衝擊,特別是退休金,以及與 COLLEAGUE 相關的交付事項(deliverables)。你能否協助我們理解,整體而言,你怎麼看 2012 年的基礎現金趨勢?你認為 2012 年何時會看到較為正常化的一季現金流?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Until we get the COLLEAGUE consent order done, we won't see a normalized quarter until the third quarter. We're targeting July as when the due date is to finalize that. The amount of cash we've assumed out the door related to COLLEAGUE in 2012 is slightly higher than it is in 2011. Those are comparable year-over-year and aren't driving a difference. You're right, we did have a pension contribution in early 2011 that we're not expecting to make a pension contribution in 2012. Nothing else really material to discuss around the overall working capital and cash flow assumptions.
在我們完成 COLLEAGUE 同意令(consent order)之前,我們要到第三季才會看到正常化的一季。我們目標是在 7 月到期日前完成定案。我們假設 2012 年因 COLLEAGUE 而流出的現金金額,略高於 2011 年。但兩年之間大致可比,並不是造成差異的主因。你說得對,我們在 2011 年初有一筆退休金提撥,但我們預期 2012 年不會再做退休金提撥。除此之外,關於整體營運資金與現金流假設,沒有其他真正重大的事項可補充。
Again, our guidance, we said, exceeds $3 billion, so we'll see how things play out. Generally, I'm very comfortable with how we've managed the inventory and DSO situations in a very tough environment, particularly DSO. You did see some slight deterioration year-over-year, but certainly nothing dramatic and it's one we're very focused on managing going forward.
再次強調,我們的指引是超過 30 億美元,所以我們會看事情如何發展。整體而言,在非常艱困的環境下,我對我們在庫存與 DSO(應收帳款週轉天數)方面的管理感到很放心,尤其是 DSO。你確實看到年對年有些微惡化,但當然並不劇烈,而這也是我們未來非常專注要持續管理的一項。
David Lewis - Analyst
David Lewis - Analyst
Okay. Two quick ones here -- Bob one more financial and one for Bob Parkinson. Just on the $0.20 to $0.25 for currency and pension, could you just give us the relative break out there between pension and currency -- or specifically, just what the pension expense, alone, is?
好的。這裡兩個快問——Bob,再一個財務問題,另外一個給 Bob Parkinson。關於匯率與退休金合計每股 0.20 到 0.25 美元的影響,你能否提供退休金與匯率之間的相對拆分——或者更具體地說,單就退休金費用本身是多少?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes. Maybe, I'll spend a bit of time on this because I think it's relevant for a lot of other folks as well. Pension is, as we projected, $0.09 of a headwind year-over-year. So, looking at the residual of $0.16, that's the midpoint of our estimate of the impact of foreign exchange. Historically, we've talked about FX being a fairly muted impact at the bottom line for the Company, a combination of having natural hedges and the use of financial hedges, and a bit of a portfolio effect in the emerging markets for us over time. In fact, if you look at 2011, despite volatility where a tailwind for us in the front half of the year and a headwind in the back half, we end the year with approximately $0.03 of a net impact on FX on the full year 2011.
可以。我可能會在這裡多花一點時間說明,因為我認為這對其他很多人也很相關。退休金如同我們先前預估,年對年是每股 0.09 美元的逆風。因此,剩餘的 0.16 美元,是我們對外匯影響估計的中位數。過去我們談到外匯對公司最終盈餘的影響相對溫和,原因包括我們有自然避險、也使用金融避險工具,以及隨時間推進在新興市場的投資組合效應。事實上,如果你看 2011 年,儘管波動很大——上半年對我們是順風、下半年是逆風——我們在 2011 全年外匯的淨影響約為每股 0.03 美元。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Favorable.
有利。
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes. Net-net, not a much of an impact to speak of on the base of $4.31 of earnings. But as we move into 2012, clearly we're projecting a much more pronounced impact. Maybe I'll just take a minute here and walk everyone through the drivers, because I think this is important.
是的。整體而言,在每股 4.31 美元的盈餘基礎上,幾乎沒有什麼影響可言。但進入 2012 年時,很明顯我們預測的影響會更為顯著。我可能在這裡花一分鐘帶大家走一遍驅動因素,因為我認為這很重要。
As we've talked about regularly, Baxter has about 60% of our revenues outside the US. We've increasingly highlighted for investors that now, slightly more than 20% of our revenues come from emerging markets, and in fact, emerging markets have been growing 2 to 3 times the rate of developed markets over the last five years. The mix of our business certainly has shifted towards emerging markets to a much greater degree.
如同我們一直以來定期討論的,Baxter 約有 60% 的營收來自美國以外。我們也愈來愈常向投資人強調,目前我們略高於 20% 的營收來自新興市場;事實上,過去五年新興市場的成長速度是已開發市場的 2 到 3 倍。我們的業務組合確實已在更大程度上轉向新興市場。
As we've highlighted in the past, for development markets, we have the ability through natural hedges, given our manufacturing footprint, which we have in places like Europe and Canada and Japan, Australia, and so on. We have some natural hedges there, but also we utilize financial hedges in those developed markets.
如同我們過去所強調的,在已開發市場方面,鑑於我們的製造據點布局(例如歐洲、加拿大、日本、澳洲等地),我們能透過自然避險來降低風險。我們在那裡有一些自然避險,同時也在這些已開發市場運用金融避險。
I would pause here to say as we've talked about in the past, by policy, we hedge 80% of our projected exposures and by the nature of hedging, when you're looking at 12 to 18 to 24 months out, you have to be careful in your projections to ensure that you don't get yourself in an overhead situation, hence the 80% with a 20% buffer. But what that does mean is we do have some residual exposure muted, but some residual exposure in the developed markets.
我在這裡先補充一下:如同我們過去談過的,依政策我們會對預估曝險的 80% 進行避險;而避險的特性是,當你看的是未來 12、18 甚至 24 個月時,你必須謹慎做預測,以確保不會讓自己處於過度避險的狀況,因此採用 80% 並保留 20% 的緩衝。但這也意味著,我們在已開發市場仍有一些剩餘曝險——雖然被削弱了,但仍然存在。
As we've said in the past, with emerging markets, we do not hedge, we do not utilize financial hedges and we have modest natural hedges -- some manufacturing facilities in Latin America, Eastern Europe and so on. But nothing near the degree we have in the developed markets. Our bottom line drop through exposure on the emerging markets is much more leveraged.
如同我們過去所說,在新興市場方面,我們不做避險,不使用金融避險工具;我們有一些有限的自然避險——例如在拉丁美洲、東歐等地有部分製造設施。但遠不及我們在已開發市場的程度。我們在新興市場的損益(底線)穿透式曝險槓桿更高。
To frame that exposure for you then, looking at it by region. So, within Latin America, from an operating profit perspective that would be exposed to foreign currency, think of that in terms of $300 million to $400 million of annual profit. That's primarily Brazil, Colombia, and Mexico. For Eastern Europe, which is primarily Russia, Poland, and Turkey -- again, about $300 million of operating profit on an annual basis.
為了讓你理解這個曝險,我們按區域來看。在拉丁美洲,從會受到外幣影響的營業利益角度來看,可把它想成每年約 3 億到 4 億美元的利潤。主要來自巴西、哥倫比亞與墨西哥。至於東歐,主要是俄羅斯、波蘭與土耳其——同樣每年約 3 億美元的營業利益。
Then in Asia-Pacific, and there, we'd exclude Japan, Australia-New Zealand, and China -- because of the stability of the currency. So, all of Asia excluding those three is another roughly $300 million of operating profit on an annual basis. You add that up, that's $900 million to $1 billion of profit exposed to currency in emerging markets. As you've seen, there's been quite a bit of volatility. Given where we're sitting today, and where rates are today relative to where they were on average in 2011, if you assume an 8% to 10% weakening across that basket of emerging market currencies, that's $80 million to $100 million of incremental exposure that we're factoring in here. You add to that the slight 20% residual impact from the developed markets that goes unhedged, and that's how we get into this $0.15 to $0.18 range of FX exposure.
接著是亞太地區;在這裡我們會排除日本、澳洲—紐西蘭以及中國——因為其貨幣相對穩定。因此,除去這三個市場後的亞洲,其每年營業利益約再有 3 億美元。加總起來,新興市場中約有 9 億到 10 億美元的利潤暴露於匯率。如你所見,波動相當大。以我們今天所處位置、以及目前匯率相對於 2011 年平均水準來看,若假設這一籃子新興市場貨幣整體貶值 8% 到 10%,我們在此納入的新增曝險約為 8,000 萬到 1 億美元。再加上已開發市場中未避險的 20% 殘餘影響,這就是我們如何得到每股盈餘約 0.15 到 0.18 美元的外匯曝險區間。
As you would imagine, given the volatility, we've assumed somewhat conservative rates relative to where market rates are today. There's been a bit of a run up here in the last few days, but given the volatility, I hesitate to call it very conservative. That's the picture. If I step back and think about, as a large US multinational corporation, and thinking about the long run, being long in the emerging markets, whether it's from a growth perspective or a currency perspective, is exactly where we want to be.
如你所想像,鑑於波動性,我們採用的假設匯率相對於今日市場匯率偏保守一些。過去幾天匯率有些反彈,但考量波動性,我不太敢說這是「非常」保守。整體情況就是如此。如果我退一步思考,作為一家大型美國跨國企業,從長期來看,無論是從成長或貨幣角度,長期布局新興市場正是我們想要的位置。
We continue to see great opportunities there, but in times of financial crisis like this where the correlation between those currencies and the US dollar is all going one way, it creates this outside exposure that we're having to factor into our guidance year for 2012. Thanks for bearing with me, but I think it's important that people understand the breadth of the issue for us.
我們仍然看到那裡有很好的機會,但在像這樣的金融危機時期,這些貨幣與美元的相關性都朝同一方向變動,便會造成我們必須納入的額外曝險,並反映在我們對 2012 年的財測指引中。謝謝你耐心聽我說,但我認為讓大家理解這個議題對我們影響的廣度很重要。
David Lewis - Analyst
David Lewis - Analyst
Thanks for the detail and I think the other Bob owes you a gold star. Maybe one more quick one for Bob Parkinson. Bob, there's been a lot of concerns here in the quarter regarding European austerity, you've talked a lot about old Europe pressures. We've been surprised about where that pressure's coming from, I think it's a little different than where the investor sees between your plasma business versus your injectable and nutritional business. Can you talk to where you're seeing the pressure and which businesses for Baxter are proving to be more robust? Then, which businesses are seeing more pharmaceutical-like pressure? Thank you.
謝謝你提供這麼多細節,我想另一位 Bob 欠你一顆金星。也許再問 Bob Parkinson 一個簡短問題。Bob,本季市場對歐洲緊縮政策有很多擔憂,你也談了很多「老歐洲」的壓力。我們對壓力來源感到意外;我認為這與投資人對你們血漿業務相較於注射劑與營養業務的看法有些不同。你能談談你看到壓力主要來自哪裡,以及 Baxter 哪些業務展現出較強韌性嗎?另外,哪些業務正承受較像製藥業那樣的壓力?謝謝。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
The negative impact of the austerity measures, first of all, is what I'll call general softness, David, in underlying demand. But these are the things we see globally. Surgical procedures and things of that nature are somewhat softer than what's been reflected historically. That would run across virtually all of our businesses, certainly even our IV business and so on and so forth.
緊縮措施的負面影響,首先我會稱之為基礎需求的普遍走弱,David。但這些其實是我們在全球都看到的現象。手術量與這類需求相較於歷史水準略為疲弱。這幾乎會橫跨我們所有業務,當然也包括我們的輸液(IV)業務等等。
But the other pressure that's probably more pronounced and is more associated with our BioScience business would be pricing pressures with governments who clearly are under the gun to implement austerity measures. Given healthcare spending and what a large item it represents on national budgets and so on. We continue to see governments virtually unilaterally implementing various pricing actions. That impact is more pronounced in things like biosurgery where people are making trade-off decisions in terms of clinical options that they have. Also, most of our BioScience products, which are more expensive. As an example, countries like France implement actions in terms of taking prices down. It's a haircut, David.
但另一個可能更明顯、且更與我們 BioScience(生物科學)業務相關的壓力,是政府端的定價壓力;政府顯然在推動緊縮措施上承受很大壓力。考量醫療支出在國家預算中占比很大等等因素。我們持續看到各國政府幾乎單方面地推行各種價格措施。這種影響在例如生物外科(biosurgery)等領域更為明顯,因為人們會在可用的臨床選項之間做取捨。也影響到我們多數較昂貴的 BioScience 產品。例如法國等國家會採取降價措施。這就是砍價,David。
It's not as pronounced as what you would see with some of the tender actions, let's say on hemophilia, because encouragingly, we haven't seen the expansion beyond the Anglo markets of the tender activity for hemophilia. We think we've captured, in our guidance for next year, those known pricing actions that will be taken on a country-by-country basis. We, also, think we've reflected the underlying softness of demand. But I think we have to be cognizant of the fact that, given the extreme austerity measures and pressures that exist -- that unlike the US, governments in Europe most notably, really have a history of implementing unilateral actions for which there's not a lot of control.
這不像你在某些招標行動(例如血友病)中看到的那麼劇烈;令人鼓舞的是,我們尚未看到血友病的招標活動擴大到英語系市場以外。我們認為,在我們對明年的財測指引中,已納入那些已知、將按國別推行的定價措施。我們也認為已反映基礎需求的走弱。但我認為我們必須意識到,在極端緊縮措施與壓力之下——不同於美國,尤其是歐洲各國政府,確實有單方面採取措施的歷史,而我們對此可控性不高。
We think we've captured it, but like I say, given the environment, I think we have to be cognizant that there could be more there. By the way, this is an ongoing thing. It's why I talk about dealing with the new environment in our Company and our culture and so on. This isn't something that's going to pass through this year -- or through the end of 2012, it's going to be with us.
我們認為已把它納入,但如我所說,考量環境因素,我們必須意識到可能還會有更多影響。順帶一提,這是一個持續性的議題。這也是為什麼我會談到公司與文化要去適應新的環境等等。這不是今年就會過去——或到 2012 年底就結束——它會一直伴隨著我們。
David Lewis - Analyst
David Lewis - Analyst
Very helpful both of you, thank you.
你們兩位的說明都非常有幫助,謝謝。
Mary Kay Ladone - Corporate VP, IR
Mary Kay Ladone - Corporate VP, IR
David, I would just add is that what we included in our 2012 guidance was what we had discussed throughout the fourth quarter of about $30 million to $40 million related to austerity measures. That's pretty balanced between both BioScience and Medical Products. I'd just highlight that the majority of the impact is really coming from vaccines within the BioScience business. And within Med Products, it's really between IV therapy, where our nutrition products are being impacted, and then some impact in renal.
David,我再補充一下:我們在 2012 年財測指引中納入的,是我們在第四季一路討論的、與緊縮措施相關約 3,000 萬到 4,000 萬美元的影響。這在 BioScience 與 Medical Products(醫療產品)之間相當平均。我想特別強調,多數影響其實來自 BioScience 業務中的疫苗。而在醫療產品方面,主要是在輸液治療(IV therapy)——我們的營養產品受到影響——以及腎臟相關業務也有一些影響。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
That's helpful. Thanks, Mary Kay.
這很有幫助。謝謝你,Mary Kay。
David Lewis - Analyst
David Lewis - Analyst
Very helpful, thank you.
非常有幫助,謝謝。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
David Roman - Analyst
David Roman - Analyst
I was wondering if you could walk through the impact of M&A on the guidance? I know you provided some perspective with respect to dilution at the time you announced the deals. But how much of the dilution that you provided then, is either going through GAAP or ongoing earnings?
我想請你說明一下併購(M&A)對財測指引的影響?我知道你們在宣布交易時,已就稀釋影響提供了一些觀點。但你們當時提到的稀釋,有多少是會反映在 GAAP 之下,或是屬於持續性的獲利稀釋?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Within the guidance that we provided, the incremental dilution is about $0.05. A couple things I'd note -- one is we did take about $0.01, roughly, in Q4 here, because we did close the Baxa acquisition a little earlier than we thought. Some of what we were projecting for '12 occurred in '11. Then, as we've looked at this further, there are certain aspects of the transaction costs that we're likely to special out going forward. But the big chunk of this really is non cash amortization related to deal premium that you have to run through, in our case, will go through cost of goods sold and that's about $35 million from an incremental headwind that's going to run through margin here. Again, about $0.05 incremental, but we did take $0.01, roughly, in Q4.
在我們提供的指引中,新增的稀釋約為 0.05 美元。我想補充幾點——第一,我們在這裡的第四季大約已承擔了 0.01 美元,因為我們完成 Baxa 收購的時間比預期稍早。因此,我們原本預估在 2012 年發生的一部分,已在 2011 年發生。接著,隨著我們進一步檢視,有些交易成本的某些項目,未來我們可能會以特殊項目方式剔除。但其中最大的一塊其實是與交易溢價相關的非現金攤銷;以我們的情況,會計入銷貨成本,約 3,500 萬美元,這將成為毛利率的額外逆風。總之,新增稀釋約 0.05 美元,但我們在第四季大約已承擔了 0.01 美元。
David Roman - Analyst
David Roman - Analyst
Okay. If I look at the plasma protein business, the issues about timing of imports in China. I think you'd talked about that last quarter as well, and you brought up the delay on a large tender for PD factory in Brazil. Are those issues that we should think about as being ongoing for the next several quarters, or will those normalize at some point whereby that business gets back to stable underlying growth on a reported basis?
了解。如果我看血漿蛋白業務,關於在中國進口時點的問題。我記得你們上季也談到過,另外也提到巴西 PD 工廠一個大型標案延後。這些問題我們應該視為未來幾季仍會持續,還是會在某個時間點正常化,讓該業務在報表口徑下回到穩定的內生成長?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes. Certainly Brazil, for sure, is a timing issue. We're hoping to continue to accelerate into China with albumin because it is a great growth opportunity. Yes, you should see normalized growth rates here in 2012 for that category.
是的。巴西當然確定是時點問題。我們希望持續加速在中國的白蛋白業務,因為那是很好的成長機會。是的,2012 年你應該會看到該類別的成長率回到正常水準。
Mary Kay Ladone - Corporate VP, IR
Mary Kay Ladone - Corporate VP, IR
Although, I would mention, David, that tenders tend to be volatile and we can see shifts from quarter to quarter. Just to highlight that.
不過我想提一下,David,標案通常波動較大,我們可能會看到季度之間的移轉。特別提醒一下。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
David, the one thing I would add too, to the China situation. There's been local action by the Chinese government to further scale back some of their local plasma collection operations in the country. This importation of albumin in China, would appear to be something that is going to be sustainable for the near future. Certainly over the next few years, I think, given some of the local issues they manage through.
David,我也想補充一下中國的情況。中國政府在當地採取行動,進一步縮減國內部分本地血漿採集作業。因此,在中國進口白蛋白,看起來在近期將會是可持續的。我認為至少在未來幾年,考量他們需要處理的一些本地問題,應該都是如此。
David Roman - Analyst
David Roman - Analyst
Okay. Lastly, on the new products, Bob, in your prepared remarks, you talked about SubQ both capturing share from your competitors as well is converting some of your own business. When we think about things like HyQ and some of the other products that you'll launch through the end of '12 and into '13, should we think about those as more share capture, market growing, cannibalistic? How would you rate that?
了解。最後,關於新產品,Bob,你在事先準備的講稿中提到 SubQ 一方面從競爭對手那裡搶市占,另一方面也會轉換你們自己的一部分業務。當我們思考像 HyQ 以及其他你們將在 2012 年底到 2013 年推出的產品時,我們應該把它們視為更多的市占取得、擴大市場,還是會有蠶食效應?你會怎麼評估?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
It will be some of each. Over time, it should translate into both share gains, but I would say, also, at a price premium. As Bob pointed out, hopefully when we get approval between then and the end of the year, we're going to have a very controlled launch. Understand what the receptivity of the product is, which then will titrate the marketing objectives between share gain pricing and so on, recognizing in the near-term managing through supply of IG. But the value in HyQ should be manifested in both share gains and pricing.
三者都會有一些。隨著時間推進,它應該會帶來市占提升,但我也會說,會伴隨價格溢價。如 Bob 所指出的,希望在我們於現在到年底之間取得核准後,我們會進行非常受控的上市推廣。先了解市場對產品的接受度,然後在市占提升、定價等行銷目標之間做調整,同時也要認知到短期內仍需管理 IG 供應。但 HyQ 的價值應會同時體現在市占提升與定價上。
David Roman - Analyst
David Roman - Analyst
Okay. Thank you very much.
了解。非常感謝。
Operator
Operator
Rick Wise, Leerink Swann.
Rick Wise,Leerink Swann。
Rick Wise - Analyst
Rick Wise - Analyst
Could I start with gross margin? Bob, you talked about gross margin being essentially flat for the year, but could you talk about it, how should we think about the quarterly flow? Particularly, as it relates to old LA shutdown -- temporary shutdown? Should we assume second half gross margins are lower? If you could help us think through that?
我可以先從毛利率開始嗎?Bob,你提到全年毛利率基本持平,但你能談談我們應該如何看待季度間的走勢嗎?特別是與舊 LA 停工——暫時停工——相關的部分?我們是否應假設下半年毛利率較低?如果你能幫我們梳理一下就太好了。
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
No, I don't think that old LA, in and of itself, given that it's back half, that we'll take it down and how that rolls through our P&L. As you know, there's a bit of a delay given the long lead time of that. Most of that impact will actually impact 2013. Again, it's a slight impact, it's not that significant. I wouldn't expect anything unusual quarter-by-quarter margin, with the exception of FX.
不,我不認為僅就舊 LA 而言,考量它發生在下半年、我們會如何處理以及它如何反映到損益表。如你所知,由於前置期很長,會有一些延遲。其影響大多其實會落在 2013 年。再說一次,影響很小,並不顯著。除了匯率(FX)之外,我不預期季度間毛利率會有任何異常。
As you know, we talked about FX as a tailwind in our Q2 margin in 2011. Then, it snapped back to a headwind given the dramatic move in emerging market currencies. Because there is a dichotomy in terms of how margin affects -- FX affects our margin between the developed markets, where we have natural hedges and financial hedges. That tends to mute the margin impact, but as reported sales come down, that can actually result in a higher reported margin percentage. But on the emerging market side because it's more highly leveraged and we don't have the financial hedges or the natural hedges in place, that tends to be more of a straight drop through. So, it really does matter which currencies are moving which way, here between developed markets and emerging markets.
如你所知,我們談過 2011 年第二季匯率對毛利率是順風。之後,由於新興市場貨幣大幅波動,它又迅速轉為逆風。因為在匯率如何影響毛利率方面存在一種二分情況——在已開發市場,我們有自然避險與金融避險。這往往會削弱對毛利率的影響,但當報表銷售額下降時,反而可能導致報表毛利率百分比更高。但在新興市場端,因為槓桿更高、且我們沒有金融避險或自然避險配置,影響往往更接近直接穿透。因此,究竟是哪些貨幣往哪個方向變動,在已開發市場與新興市場之間,確實很重要。
The one caveat to my comment, really, is that the tailwind in Q2 and the headwind in Q3 versus where we're at here with 2012 and our initial guidance, that would be the only tweak. I don't think it's anything dramatic there.
對我剛才評論唯一需要保留的是:2011 年第二季的順風與第三季的逆風,相較於我們目前對 2012 年的情況與初始指引,那會是唯一需要微調之處。我不認為那裡會有什麼劇烈變化。
Mary Kay Ladone - Corporate VP, IR
Mary Kay Ladone - Corporate VP, IR
Rick, I'd add that, I think Bob mentioned earlier, our Q1 gross margin is expected really to be flat to 2011 Q1. Q2, generally, we do see a higher margin really due to the mix of our sales, which is benefited by the FSME vaccine, which is very high margin. Typically, Q2 is our highest gross margin quarter of the year, and then in Q3 and Q4, it moderates a little bit.
Rick,我補充一下,我想 Bob 先前提到,我們預期第一季毛利率基本上會與 2011 年第一季持平。第二季一般而言毛利率會較高,主要是因為銷售組合的關係,受惠於 FSME 疫苗,而它的毛利率非常高。通常第二季是我們全年毛利率最高的季度,之後在第三季與第四季會稍微回落一些。
Rick Wise - Analyst
Rick Wise - Analyst
Okay. That's helpful. If I could turn to the plasma market, you've talked about some of the market dynamics, but it seems like as we look at 2012, the outlook is a lot different than a year ago. Grifols Talecris now combined, two questions -- can you talk about the dynamics of the consolidation -- the Octapharma $100 million you've taken out? Are you seeing them on track to actually do that or is that a conservative assumption? Maybe a little bit about, collections and supply-demand, I would appreciate it. Thank you.
了解。這很有幫助。如果我轉到血漿市場,你們談過一些市場動態,但看起來我們看 2012 年時,展望和一年前差異很大。Grifols 與 Talecris 現在已合併,有兩個問題——你能談談整併的動態嗎——以及你們假設 Octapharma 會減少的 1 億美元(你們已從中扣除)?你們看到他們確實有望做到,還是那是較保守的假設?另外也請談談採漿量與供需狀況,我會很感謝。謝謝。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Rick, this is Bob Parkinson. Let me take the first part and maybe you can address, Bob, collections. I really don't want to comment in terms of competitive response, and I know there's been a lot of changes in the market, frankly, as a result of what we've seen. Clearly, Octapharma has gotten a lot of business back already that we gained from them last year. Whether our assumption is conservative or not is yet to be seen. But I think it is fair to say that most of the volume that we gained will get lost back over time to them. Okay?
Rick,我是 Bob Parkinson。我先回答前半段,然後也許你可以談談,Bob,關於收款。我真的不想就競爭回應發表評論,而且我知道市場上確實有很多變化,坦白說,這些變化是我們所看到的情況所導致的。很明顯地,Octapharma 已經拿回了不少我們去年從他們那裡爭取到的業務。我們的假設是否保守,還有待觀察。但我認為可以公平地說,我們所增加的大部分量,隨著時間推移會流失回到他們那邊。好嗎?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Rick, the way I would think about that is that given how the market breakdown for us in the US -- where about half of our sales in the hospital, acute, episodic use versus the chronic space. Our focus, particularly with SubQ and then with HyQ, is really going to be grow out the chronic space. So, with that differentiation, we think we have great opportunities there. Where they play today given their 5% concentration, which is a sub-optimal product relative to what most other competitors have with a 10% concentration, likely they're going to play in the more price-sensitive hospital space in any case.
Rick,我會這樣看:就我們在美國的市場結構而言——我們大約一半的銷售是在醫院端,屬於急性、間歇性使用;另一半則在慢性用藥領域。我們的重點,特別是 SubQ,接著是 HyQ,確實會放在擴大慢性用藥市場。因此,憑藉這種差異化,我們認為那裡有很好的機會。而他們目前的產品是 5% 濃度,相較於多數其他競爭對手的 10% 濃度,屬於較不理想的產品,所以他們很可能無論如何都會在對價格更敏感的醫院市場競爭。
For us, it's more about directing product to those parts of the channel that we think we have the best opportunity to win and if that means some of the price-sensitive accounts we lose, then so be it. It's more of how we're focusing on where we want to drive growth in the future than trying to fight it out with them hospital to hospital.
對我們而言,更重要的是把產品導向我們認為最有機會勝出的通路區塊;如果這代表我們會失去一些對價格敏感的客戶,那也就如此。這更多是我們在聚焦未來要在哪裡推動成長,而不是試圖在每一家醫院與他們逐一硬碰硬。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
What was your question, Rick, on inventories, again?
Rick,你剛才關於庫存的問題是什麼?再說一次?
Rick Wise - Analyst
Rick Wise - Analyst
It was supply-demand, given the weakening economy, are collections growing? Just wondering how you see the background there for plasma protein?
是供需面:在經濟走弱的情況下,收款(collections)有在增加嗎?只是想了解你怎麼看血漿蛋白這一塊的背景狀況?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Actually, the economic environment in the area of plasma proteins in general -- certainly in IG, frankly, we haven't seen -- little to no effect, really, in terms of underlying demand. I think in terms of the projection of market growth, both in '12 and going forward beyond that, very consistent with what we've communicated before. I would say strong single-digit, mid single-digits. That's for the total market. Obviously, with the early encouraging feedback on our SubQ product, the hopeful launch of HyQ and then indication expansions with MMN and so on over time. It's clearly our aspiration to grow this business at a faster rate than the overall market. But overall, Rick, pretty stable.
其實,整體血漿蛋白領域的經濟環境——尤其是在 IG 方面,坦白說,我們幾乎沒有看到任何影響,或是對基礎需求幾乎沒有影響。我認為就市場成長的預測而言,無論是 2012 年或之後,與我們先前溝通的內容都非常一致。我會說是強勁的個位數成長、中個位數成長。那是整體市場。當然,隨著我們 SubQ 產品早期令人鼓舞的回饋、HyQ 有望上市,以及未來像 MMN 等適應症擴增等。我們顯然希望這項業務能以高於整體市場的速度成長。但整體而言,Rick,相當穩定。
Rick Wise - Analyst
Rick Wise - Analyst
Thanks, so much.
非常感謝。
Operator
Operator
Bob Hopkins, Bank of America Merrill Lynch.
美國銀行美林(Bank of America Merrill Lynch)的 Bob Hopkins。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Two quick questions -- one on the Analyst Day, upcoming. Then, another on your recent press release on Alzheimer's and the futility analysis that was done. On the futility analysis, I was wondering if you could just comment a little bit more specifically about what we should and should not read into that analysis and the 20% threshold. It's my understanding that relates specifically to safety, and says nothing about efficacy related to that 20%. Is that the right way to look at it? I just want to clarify the point because it has impacted the stock.
兩個很快的問題——一個是關於即將到來的分析師日(Analyst Day)。另一個是關於你們最近針對阿茲海默症以及所做的無效性(futility)分析的新聞稿。就無效性分析而言,我想請你更具體地評論一下:我們應該、以及不應該,從該分析與 20% 門檻解讀出什麼。我的理解是,那個門檻是特別與安全性相關,對療效並沒有任何說明,至少不會因為 20% 而代表療效。這樣理解對嗎?我只是想釐清這點,因為它已經影響到股價。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
As Mary Kay mentioned at the outset, Dr. Norbert Riedel's with us this morning. I'm going to ask Norbert to respond to your question on this. Go ahead, Norbert.
如同 Mary Kay 一開始提到的,Dr.Norbert Riedel 今天早上也在現場。我會請 Norbert 回答你這個問題。Norbert,請。
Norbert Riedel - Corporate VP, Chief Science and Innovation Officer
Norbert Riedel - Corporate VP, Chief Science and Innovation Officer
Okay. Maybe just for a little bit of context, the Phase III trial that is ongoing has about 390 patients enrolled. Patients are on therapy for 18 months. The futility analysis was done on a 120 patient, part of that trial that has already completed 18 months on therapy. The Alzheimer's consortium, who we worked with to conduct this trial, had a statistical group determine the parameters of the futility analysis. For it to be truly within the spirit of the futility analysis and not become de facto interim analysis -- and that's where they set the cut off for the assessment. The assessment was done -- and says that there is a better than 20% probability of reaching the endpoints, the primary endpoints defined for the trial.
好的。先提供一點背景:目前進行中的第三期試驗大約納入了 390 位病人。病人接受治療 18 個月。這次的無效性分析,是針對其中已完成 18 個月治療的 120 位病人所做。我們與阿茲海默症聯盟(Alzheimer's consortium)合作執行這項試驗,由他們的統計團隊決定無效性分析的參數。為了真正符合無效性分析的精神,而不是事實上變成期中分析——因此他們設定了評估的截點。評估結果顯示——達成試驗所定義主要終點(primary endpoints)的機率高於 20%。
There's also no indication, from a safety point of view, as to why the trial should not proceed. Therefore, the recommendation that the trial should indeed proceed as planned. Our communication that we will be initiating a second conservatory trial with the exact same trial design.
此外,從安全性的角度來看,也沒有任何跡象顯示試驗不應繼續。因此,建議是試驗應按計畫繼續進行。我們也已對外溝通:我們將啟動第二個確認性(confirmatory)試驗,採用完全相同的試驗設計。
Specifically, answering your question, I did not expect a safety signal or a safety concern, primarily because immunoglobulin, GAMMAGARD is used and has been used for very many years in primary immunodeficiency and has a very well-defined and also, I would say, a very favorable safety profile. Safety was not really the issue -- why it was looked at anyway by the DSMB. But it was about a probability assessment that we will indeed be able to achieve the primary endpoint. So, I'm encouraged by that.
具體回答你的問題:我並不預期會出現安全性訊號或安全性疑慮,主要是因為免疫球蛋白、GAMMAGARD 長年用於原發性免疫缺乏症,且其安全性特徵非常明確,我也會說相當良好。安全性其實不是問題——儘管 DSMB 仍然會檢視。重點在於對我們是否確實能達成主要終點所做的機率評估。所以,這讓我感到鼓舞。
I think it supports, also, the Phase II trial data that we have seen, it supports our hypothesis that a multi-factorial disease like Alzheimer's disease will likely benefit from a multi-factorial treatment approach like the complexity of the immunoglobulins that we offer these patients. It just overall continues to make me cautiously optimistic that this might indeed be a way of going after treating the disease.
我認為這也支持我們所看到的第二期試驗數據,並支持我們的假設:像阿茲海默症這種多因素疾病,可能會受益於多因素的治療方式,例如我們提供給病人的免疫球蛋白所具備的複雜性。整體而言,這讓我保持審慎樂觀,認為這或許確實是一條可用來嘗試治療該疾病的途徑。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Can you just remind me the primary endpoint of the study?
你能再提醒我一下這項研究的主要終點是什麼嗎?
Norbert Riedel - Corporate VP, Chief Science and Innovation Officer
Norbert Riedel - Corporate VP, Chief Science and Innovation Officer
The primary endpoint is two well-defined endpoints that are generally used in the space of Alzheimer's disease. One is an assessment scale that is a cognitive function assessment scale that is used. The other is an overall function of the patient that has to do with activities of daily life and so on. Parameters that we have selected together with the FDA and that are consistent with endpoints in Alzheimer's trials typically looked for.
主要終點是兩個明確定義的終點,通常用於阿茲海默症領域。其中一個是評估量表,是用來評估認知功能的量表。另一個是病人的整體功能,與日常生活活動等相關。這些參數是我們與 FDA 一起選定的,也與阿茲海默症試驗中通常採用的終點一致。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Great, thank you very much.
很好,非常感謝。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
What's your question on Investors Day, then, Bob?
那你關於投資人日(Investors Day)的問題是什麼,Bob?
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Yes. On the Investors Day, just some thoughts on specific timing and things that you're going to be covering on that day that you think we should be aware of in front of the meeting, and things that we should be preparing for?
是的。關於投資人日,我想聽聽你們對具體時間安排,以及當天會涵蓋哪些主題的想法;有哪些你們認為我們在會議前應該先知道的,以及我們應該做哪些準備?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
In terms of the specific time and date, Mary Kay will be out to all of you shortly. We're nailing that down. It'll be this fall, okay? Mary Kay, within what time frame?
至於具體時間與日期,Mary Kay 很快會通知各位。我們正在把它敲定。會在今年秋天,好嗎?Mary Kay,大概在什麼時間範圍內?
Mary Kay Ladone - Corporate VP, IR
Mary Kay Ladone - Corporate VP, IR
Within a week or two.
一到兩週內。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Within a week or two, we'll get you all the specifics in terms of the logistical part of it. But what's our objective, as we traditionally have done, is to give you a longer-term view of where we see our Company going. One of the reasons, as I've commented before, that we have not had an Investors Day for while, I think, is really largely a result of the external environment and recognizing the volatility that existed. Candidly, we wanted to get a better line of sight both in terms of our operating plan for 2012 as a baseline, but to get our arms around some of the moving parts.
一到兩週內,我們會把後勤安排等所有細節提供給各位。但我們的目標,如同我們過去一貫所做的,是讓各位看到我們對公司未來走向的較長期觀點。我之前也提過,我們有一段時間沒有舉辦投資人日,其中一個原因,我認為,很大程度上是外部環境所致,也就是我們意識到當時存在的波動性。坦白說,我們希望能更清楚掌握視野:一方面以 2012 年的營運計畫作為基準,另一方面也要把一些變動因素梳理清楚。
I think you can interpret the fact that we're scheduling that as positive in terms of our sense that we think we more definitively have our arms around where we're going and so on. It's a bit of a sense of confidence, as you gathered, from my prepared comments. We continue to be very confident in the long-term outlook of the Company. We understand all of you have been waiting for a while to get a sense of something beyond the immediate year that we're operating in.
我認為,你可以把我們安排這件事解讀為正面訊號,代表我們覺得自己對未來方向更有把握、也更能掌握全局等。正如你從我事先準備的發言中所感受到的,這帶有一點信心的意味。我們對公司長期展望仍然非常有信心。我們也理解,各位已經等了一段時間,希望能看到超越我們目前營運這一年的一些方向感。
That's really the primary objective in terms of what's going to drive the growth of the Company going forward. Really, at what rate do we see revenue growing out over the coming years, as well as projected earnings growth and so on. We look forward to getting together with everybody.
這確實是推動公司未來成長的首要目標。也就是說,未來幾年我們預期營收會以什麼速度成長,以及預估獲利成長等。我們期待與各位相聚。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Thanks very much.
非常感謝。
Operator
Operator
Larry Keusch of Morgan Keegan.
摩根基根(Morgan Keegan)的 Larry Keusch。
Larry Keusch - Analyst
Larry Keusch - Analyst
I'm just wondering, Bob, if you might just -- I know we spent some time on Octapharma, but maybe just from a global perspective, help us understand what you're seeing on price globally? Again, I understand you don't want to compete in most price sensitive countries or hospitals in the US, but just what they're doing?
我只是想請教一下,Bob,你是否可以——我知道我們花了一些時間談 Octapharma,但也許從全球角度,幫我們理解你們看到的全球價格走勢?同樣地,我理解你們不想在多數對價格高度敏感的國家或美國的醫院市場競爭,但他們到底在做什麼?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
I'll just comment to some degree, maybe not satisfying you specifically. But from our perspective -- obviously, we're seeing fairly stable prices in terms of what we charged our customers around the world. I'll leave it at that.
我只能在某種程度上做些評論,可能無法完全回答你的具體問題。但從我們的角度——很明顯,我們看到在全球範圍內對客戶的收費價格相當穩定。我就先說到這裡。
Larry Keusch - Analyst
Larry Keusch - Analyst
Okay. Then, obviously, emerging markets are already a big proportion of your business. There's a lot of reasons to believe that, and Bob Hombach mentioned they're clearly the right place to invest in this is where you want to go long term. I think you've thrown out 30% as a percent of sales of where you think these markets can go. Can you just remind us of how you're thinking about when you might reach that bogie? How we should be thinking about the margin profile, as the mix of emerging markets gets bigger?
好的。那麼,很明顯新興市場已經占你們業務相當大的比重。有很多理由相信這點,而且 Bob Hombach 也提到,這些市場顯然是正確的投資方向、也是你們長期要去的地方。我記得你們提過 30% 作為你們認為這些市場可達到的銷售占比。能否提醒我們,你們怎麼看何時可能達到這個目標?當新興市場占比提高時,我們應該如何看待毛利/利潤率結構?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Let me make a couple of comments and then Mary Kay and Bob can add to this. First of all, this will be an area of focus at our Investor Conference this fall. We'll hone in, provide a little more structure and definition on the opportunity that we see long-term associated with emerging developing markets. I think the number that you cited, clearly, is a reasonable aspiration that we ought to be able to get to within a five-year period of time, to give you little bit of a framework.
我先講幾點,接著 Mary Kay 和 Bob 也可以補充。首先,這將是我們今年秋季投資人會議的重點議題之一。我們會更聚焦,並對我們長期所看到、與新興開發中市場相關的機會提供更多架構與定義。我認為你提到的那個數字,顯然是一個合理的目標;給你一個框架,我們應該能在五年內達成。
In terms of profitability, actually, interestingly, if you look at pretax operating margin as a percent of sales in these markets, it actually aligns fairly closely with what we see in developed markets. Obviously, the cost of doing business in not all, but many, of these markets is much less. Also, we're supporting this growth through overhead structure, whether it's here in our corporate offices or in our regional offices that can be further leveraged. I don't see, over time a dilution to the profile of our P&L as we grow emerging and developing market revenues at a faster rate than the rest of the Company. Mary Kay or Bob if you want to add to that?
就獲利能力而言,其實很有意思:如果你看這些市場的稅前營業利益率占銷售比重,與我們在已開發市場看到的其實相當接近。很明顯,在不是全部、但許多這類市場中,經營成本要低得多。此外,我們也透過管理費用結構來支撐成長,不論是在總部或區域辦公室,都還能進一步槓桿化。因此,隨著新興與開發中市場營收成長速度快於公司其他部分,長期來看我不認為會稀釋我們損益表的整體輪廓。Mary Kay 或 Bob,你們要補充嗎?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
We've tended to enter these markets over time in the IV or renal space, but the opportunity to -- as these economies move up the scale and start devoting more of their GDP towards healthcare, some of our higher-end products, particularly biologics, become more attractive. The opportunity to increase margin, through further penetration of the biologics portfolio and the higher end projects within our Med Products space -- like some of our nutrition and anesthesia products, we actually see nice margin opportunities for improvement going forward there.
我們過去進入這些市場時,往往是從靜脈輸液(IV)或腎臟領域切入;但隨著這些經濟體往上發展、開始把更多 GDP 投入醫療保健,我們一些較高端的產品——特別是生物製劑——會變得更具吸引力。透過進一步提高生物製劑產品組合的滲透率,以及我們醫療產品事業中較高端的專案——例如部分營養與麻醉產品——我們確實看到未來有不錯的毛利/利潤率提升機會。
Larry Keusch - Analyst
Larry Keusch - Analyst
Terrific. Just one last housekeeping item for Bob Hombach. I don't know if I missed this on the call, but CapEx spending for 2012? How much is contemplated in there for the improvements being made to the old LA frac? Also, what are you assuming in your guidance for the R&D tax credit?
太好了。最後一個例行問題想問 Bob Hombach。我不確定是否在電話會議中漏聽了:2012 年的資本支出(CapEx)是多少?其中有多少是用於對舊的 LA 分餾廠(frac)的改善?另外,你們在財測指引中對研發稅額抵減(R&D tax credit)是怎麼假設的?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes, the R&D tax credit for us is a fairly small item, not material. As a relates to CapEx, once again, we're looking at about $1 billion. That may go up a little bit pending the timing of when we launch the greenfield site that we've talked about for the plasma business. But thinking about it at approximately $1 billion at this point is a good way to think about it.
是的,對我們而言研發稅額抵減是一個相當小的項目,不具重大性。至於資本支出,再次說明,我們預估大約是 10 億美元。這個數字可能會因我們先前談到、血漿業務的綠地新廠(greenfield site)啟動時點而略有上調。但目前以約 10 億美元來看待,是一個不錯的方式。
Larry Keusch - Analyst
Larry Keusch - Analyst
Okay. Terrific. Thank you.
好的。太好了。謝謝。
Mary Kay Ladone - Corporate VP, IR
Mary Kay Ladone - Corporate VP, IR
We have time for two more questions.
我們還有時間再問兩個問題。
Operator
Operator
Kristen Stewart, Deutsche Bank.
德意志銀行(Deutsche Bank)的 Kristen Stewart。
Kristen Stewart - Analyst
Kristen Stewart - Analyst
Just wanted to confirm -- sorry if I missed is the beginning -- but your guidance does include both the Baxa acquisition, and does it include Synovis? I know that hasn't closed yet, but --
我想確認一下——抱歉如果我漏聽了開頭——你們的指引包含 Baxa 這筆收購,並且也包含 Synovis 嗎?我知道那筆交易還沒完成,但——
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes.
是的。
Kristen Stewart - Analyst
Kristen Stewart - Analyst
In total, what was the total dilution from both of those deals that's included within the adjusted number?
合計而言,這兩筆交易在調整後數字中所包含的總稀釋是多少?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Within the adjusted number, we talked about $0.05 incremental in '12. We took about $0.01 in Q4 here, withholding Baxa little bit early. That's a number. As I mentioned, there are some one-time costs related to Synovis as a public Company that we'll think about specialing out -- but think about $0.05. Again, almost exclusively non-cash amortization that's required by purchase accounting that runs through margin.
在調整後數字中,我們談到 2012 年會增加約 0.05 美元的影響。我們在這裡的第四季先認列了約 0.01 美元,因為 Baxa 稍微提早納入。這就是那個數字。如我提到的,Synovis 作為一家上市公司會有一些一次性成本,我們會考慮作為特殊項目剔除——但整體就以 0.05 美元來看。另外,幾乎完全是依購買會計要求所產生的非現金攤銷,會反映在利潤率中。
Kristen Stewart - Analyst
Kristen Stewart - Analyst
Earlier I thought you had said that was running through cost of goods sold, is that correct?
我先前以為你說那是走在銷貨成本(cost of goods sold)裡面,對嗎?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes.
是的。
Kristen Stewart - Analyst
Kristen Stewart - Analyst
Bob, just a big picture question. I know biosimilars is something that, in the past, you had shied away from. Obviously, you just announced the recent deal and seems to be a little bit more clarity. Can you just maybe expand about your thoughts on biosimilars? Just where you see Baxter participating over the longer haul? Any specifics on products that you could share?
Bob,問一個比較宏觀的問題。我知道生物相似藥(biosimilars)是你們過去曾經比較避開的領域。但你們剛宣布了近期的交易,似乎也更清楚一些了。你能否多談談你們對生物相似藥的看法?你們認為 Baxter 長期會如何參與?有沒有任何可以分享的產品細節?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Yes, Kristin, with the deal Momenta, we think this could be a meaningful opportunity for our Company. Historically, it wasn't so much that we shied away from it. I think we always felt, fundamentally, we were probably as well-positioned as anyone to participate in the market.
是的,Kristin,透過與 Momenta 的交易,我們認為這可能是公司一個具意義的機會。從歷史來看,並不是我們刻意避開。我想我們一直覺得,從根本上說,我們在參與這個市場方面的定位不比任何人差。
Clearly, there was -- and continues to be, to a great degree, some ambiguity in the regulatory pathway. But if you look at Baxter's expertise in biologic manufacturing, all these are drugs that are administered -- are injectable, which plays to a Baxter strength in terms of packaging, formulation technology and so on. Obviously, given our global channel presence, again, I think we've always been as well-positioned as anyone. The reason we've been historically noncommittal was, one, lacking definition on the regulatory pathway. But with the collaboration with Momenta, candidly, we think we have a potential fundamental differentiator here at least on the six compounds that are part of the deal that we did with Momenta.
很明顯,監管途徑一直——而且在很大程度上至今仍——存在一些不確定性。但如果你看 Baxter 在生物製劑製造方面的專業,這些藥物都是以注射方式給藥,這也符合 Baxter 在包裝、配方技術等方面的強項。再加上我們的全球通路布局,我認為我們一直都具備不輸任何人的優勢。我們過去之所以態度較不明確,一是因為監管途徑缺乏明確定義。但坦白說,透過與 Momenta 的合作,我們認為至少在這筆與 Momenta 交易所涵蓋的六個化合物上,我們可能擁有一個根本性的差異化優勢。
Not to get into a lot of detail on their technology. But at least with one biologic, they have a proven track record of applying their technology, bringing it through regulatory approval and getting it launched to the market. We're excited about the prospects of potentially being able to minimize the clinical development spend given their ability to characterize these biosimilars more effectively, and accelerate the time-to-market, as well as lower cost of market as well.
不深入談他們的技術細節。但至少就其中一項生物製劑而言,他們已證明能運用其技術,推進至法規核准並成功上市。我們對於有機會憑藉他們更有效表徵這些生物相似藥的能力,來降低臨床開發支出、加速上市時程,以及同時降低上市成本,感到相當振奮。
With the Momenta deal, I think that was really the key thing that pushed us over the edge to say -- okay, we ought to be able to leverage the other Baxter strengths and take advantage of this is as a significant opportunity. We're quite excited about it.
就 Momenta 這筆交易而言,我認為那確實是讓我們下定決心的關鍵因素——也就是說,好吧,我們應該能夠槓桿運用 Baxter 的其他優勢,並把這視為一個重大的機會加以把握。我們對此相當興奮。
Kristen Stewart - Analyst
Kristen Stewart - Analyst
Congratulations on stealing Jean-Luc Butel from Medtronic. Anything different that we can expect from him with the international business?
恭喜你們從美敦力挖走 Jean-Luc Butel。在國際業務方面,我們可以期待他帶來什麼不同嗎?
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
I don't think so. Since Ludwig Hantson moved from the international role to run BioScience -- which I would say he's doing an outstanding job with our pipeline and clinical development throughout BioScience -- in the meantime, the regional presidents in Europe, Latin America, and Asia-Pacific have reported directly to me. I think that's worked fine, but I think that, as we've discussed on the call this morning -- given the opportunity in emerging developing markets, there's probably very few people in the industry have Jean-Luc's expertise and depth of experience in operating in these markets around the world. I think he will bring real value add to, and direction to, our international regions. As well as depth of experience in our senior leadership team overall. We couldn't be more pleased to have Jean-Luc come on board in a few weeks.
我想不會。自從 Ludwig Hantson 從國際職務轉任負責 BioScience——我會說他在我們 BioScience 的產品線與臨床開發方面做得非常出色——在此期間,歐洲、拉丁美洲與亞太地區的區域總裁都直接向我彙報。我認為這樣運作得很好,但正如我們今天早上在電話會議中討論的——鑑於新興發展市場的機會,業界恐怕很少有人能像 Jean-Luc 一樣,具備在全球這些市場營運的專業能力與深厚經驗。我認為他將為我們的國際區域帶來真正的附加價值與方向。同時也會為我們整體高階領導團隊帶來更深的經驗厚度。我們非常高興 Jean-Luc 將在幾週後加入我們。
Kristen Stewart - Analyst
Kristen Stewart - Analyst
Thank you.
謝謝。
Operator
Operator
Matt Miksic, Piper Jaffray.
Matt Miksic,Piper Jaffray。
Matt Miksic - Analyst
Matt Miksic - Analyst
I've got one question on some of your new products in IVIG that you've mentioned, recent and forthcoming launches of SubQ and HyQ and the offsetting impact on the return of Octa. Can you give us a sense of how SubQ has impacted your business so far? Understanding HyQ is significantly more differentiated, SubQ also seems to have been having a positive effect. Do you think it's -- if you can quantify that, is it $10 million, $50 million on an annualized basis? Or 1% or 2% incremental to your business? Then maybe at a higher level, looking at both SubQ and HyQ, do think they reach level in 2012 to offset the $100 million you've talked about giving back to Octa? Any kind of color would be great on that. I've got one follow-up.
我有一個問題,關於你們在 IVIG 方面提到的一些新產品,包括近期與即將推出的 SubQ 和 HyQ,以及它們對 Octa 回歸所帶來的抵銷影響。你們能否讓我們了解一下 SubQ 迄今對你們業務的影響?我理解 HyQ 的差異化程度明顯更高,但 SubQ 似乎也帶來了正面效果。你們認為——如果可以量化的話——按年化基礎來看,是 1,000 萬美元、5,000 萬美元?或是對你們業務帶來 1% 或 2% 的增量?再從更高層次來看,同時考量 SubQ 與 HyQ,你們認為它們在 2012 年是否能達到足以抵銷你們所說要回吐給 Octa 的 1 億美元的水準?任何相關補充說明都很有幫助。我還有一個追問。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Let me just maybe give you a general response and then Mary Kay or Bob can maybe fill in some of the details. Obviously, we're encouraged by the early response to the SubQ. We are seeing a conversion of patients from competitive product, as well as conversion of Baxter products on the IV form as well. So, we're -- with a low injection site reaction in terms of side effects which is in the label, and that's been validated I think in terms of actual clinical experience.
我先給一個較概括的回覆,接著 Mary Kay 或 Bob 也許可以補充一些細節。顯然,我們對 SubQ 的早期反應感到鼓舞。我們看到病患從競品轉換過來,也看到 Baxter 自家 IV 劑型的病患轉換過來。因此,我們——就注射部位反應而言,副作用發生率較低,這已寫在標籤上,我認為也在實際臨床使用經驗中得到驗證。
Having said that, I think it's too early maybe to quantify, Matt, how much of the Octapharma loss could be offset with the 10% SubQ, but I think it's fair to say that some of it will be. I'll stop there. Bob or Mary Kay, do you want to add to that?
話雖如此,Matt,我認為現在可能還太早去量化 10% SubQ 能抵銷多少 Octapharma 的流失,但我想可以公平地說,其中一部分會被抵銷。我先說到這裡。Bob 或 Mary Kay,你們要補充嗎?
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Yes. I get very excited about how SubQ has gone so far. But again, I would think but 2012 as a little bit of an unusual year, taking the old LA facility down. It's going to constrain our ability to grow faster than what we have described here to some degree. So, it's really about seeding the market for what we think will be a very successful HyQ launch. It will be more over time than an immediate impact in '12 -- in terms of what it might do for our business. But, clearly, it's being well-received. And again, it's the fastest growing segment of the PID market, so we're very happy to be participating in it.
是的。我對 SubQ 迄今的進展感到非常振奮。但同樣地,我會認為 2012 年是有點不尋常的一年,因為我們要把舊的洛杉磯(LA)廠房關停。這在某種程度上會限制我們比目前所描述的更快成長的能力。所以,這更關乎為我們認為將非常成功的 HyQ 上市做市場鋪墊。就它對我們業務可能帶來的影響而言,會是隨時間累積,而不是在 2012 年立即顯現。但很明顯,市場反應良好。而且這是 PID 市場成長最快的區隔,所以我們很高興能參與其中。
Matt Miksic - Analyst
Matt Miksic - Analyst
That's great. Lastly on Recombinants, with Q4, we saw a pretty significant step up in the second half of the year. I wanted to get a sense, as you head into 2012, got your growth expectations in your prepared remarks, but Dr. Riedel's been talking about the peer-reviewed paper on inhibitor formation published last summer.
很好。最後一個關於重組產品(Recombinants)問題:在第四季,我們看到下半年有相當顯著的躍升。我想了解一下,當你們進入 2012 年時,你們在事先準備的發言中提到成長預期,但 Dr.Riedel 一直在談去年夏天發表、經同儕審查的抑制物形成(inhibitor formation)論文。
Can you give a sense and maybe Dr. Riedel can answer this, as to how that paper, what kind of impact has that had on the thinking across clinicians and folks in the community? Are you starting to see an impact or do expect to see an impact whether it's in tenders or utilization? Thanks.
你們能否說明一下——也許 Dr.Riedel 可以回答——那篇論文對臨床醫師以及社群人士的思維帶來了什麼影響?你們是否開始看到影響,或預期會看到影響,不論是在標案(tenders)或使用量(utilization)上?謝謝。
Norbert Riedel - Corporate VP, Chief Science and Innovation Officer
Norbert Riedel - Corporate VP, Chief Science and Innovation Officer
Maybe I start with just touching on the paper that you refer to, the meta-analysis. Which, really, for the first time, provides a rather encompassing comparison between B-domain deleted Factor VIII and full-length Factor VIII. I keep pointing out that our ADVATE as the gold standard of therapy in hemophilia A is a full-length Recombinant Factor VIII that is manufactured completely in the absence of any proteins added, at any point in the process of making the finished product.
我先從你提到的那篇論文,也就是統合分析(meta-analysis),稍作回應。它確實是首次提供了 B 區段缺失(B-domain deleted)的第八凝血因子與全長(full-length)第八凝血因子之間相當全面的比較。我一直強調,我們的 ADVATE 作為 A 型血友病治療的黃金標準,是一種全長的重組第八凝血因子,且在製造成最終成品的整個過程中,完全不添加任何蛋白質。
I have always believed that, a full-length Factor VIII most closely mimics what is naturally occurring when you have a Factor VIII. The data in the meta-analysis suggests that B-domain deleted Factor VIII has a much higher incidence of inhibitor formation, about a sevenfold higher incidence than a full-length Factor VIII. With respect to what we call high titer antibodies, which are the most problematic for a hemophilia patient, an 11 times higher incidence rate.
我一直相信,全長第八凝血因子最能模擬體內自然存在的第八凝血因子狀態。該統合分析的數據顯示,B 區段缺失的第八凝血因子形成抑制物的發生率高得多,約為全長第八凝血因子的 7 倍。至於我們所稱的高效價抗體(high titer antibodies)——這對血友病患者最具問題——其發生率高出 11 倍。
We have been very clear with ourselves that our goal continues to be, to optimize ADVATE therapy. Our longer acting Factor VIII is fundamentally an ADVATE molecule with a minor tweak that we put on the molecule and continues our approach to working with the full-length Factor VIII. I think when you look at just the market share of B-domain deleted Factor VIII today, it is actually very small. I believe that given a choice, a full-length Factor XIII is a very attractive therapy and as I mentioned, is much closer to the natural way of dealing with bleeds or stopping the bleeds.
我們對自己非常清楚:我們的目標仍是持續優化 ADVATE 治療。我們的長效第八凝血因子,本質上是 ADVATE 分子,只是在分子上做了小幅調整,並延續我們以全長第八凝血因子為核心的策略。我認為,當你看目前 B 區段缺失第八凝血因子的市占率,其實非常小。我相信在有選擇的情況下,全長第十三凝血因子是一種非常有吸引力的治療;而且如我所提,它更接近身體自然處理出血或止血的方式。
Bob Hombach - Corporate VP and CFO
Bob Hombach - Corporate VP and CFO
Fair to say, I think, that we're starting to see this resonate more with treaters and patients, both the [PROPOFOL] label as well as the meta-analysis. But that's part of our challenge in '12 is to drive that into the market and make it happen. That's what we're focused on.
我想可以說,我們開始看到這點在治療者與患者之間引起更多共鳴,包括 [PROPOFOL] 標籤以及該統合分析。但這也是我們在 2012 年的挑戰之一:要把這些訊息推進市場並促成實際發生。這就是我們的重點。
Matt Miksic - Analyst
Matt Miksic - Analyst
Great, thank you.
很好,謝謝。
Bob Parkinson - Chairman, CEO
Bob Parkinson - Chairman, CEO
Thanks, Matt.
謝謝,Matt。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.
各位女士、先生,Baxter International 今日的電話會議到此結束。感謝各位參與。